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Abstract
Characterization of extracellular vesicles from human diabetic retinopathy retinal tissue
in vitro and from urine of human patients with diabetic retinopathy
by
Jason Mighty
Advisor: Stephen Redenti
Diabetic Retinopathy
Diabetic Retinopathy (DR) is a neurovascular complication associated with diabetes
mellitus that affects approximately 120 million people worldwide and its prevalence is
expected to reach 190 million by 2030. DR diagnosis is accomplished with fundus
ophthalmoscopy often when retinal damage and vision loss have already occurred. A
group of biomarker being explored for early detection of diseases are extracellular
vesicles (EVs), which are nanometer diameter lipid enclosed vesicles, released from all
cell types and containing genetic cargo reflective of releasing cell state. EV biomarkers
are currently being explored to help monitor disease predisposition, pathogenesis and
response to treatment. While an increasing number of studies are analyzing EVs in the
brain, EV morphology, release rates and content have yet to be elucidated in retinal
disease. The approach to characterizing retinal EVs in this work is based on the premise
that unique aspects of DR retinal cell expression patterns can be detected in retinal EV
release rate and genetic cargo. This initial work has identified molecular signatures that
have been shown to be involved in DR pathogenesis to be present in EVs and may be
built on in future studies to develop a biomarker for early detection of DR prior to retinal
damage and vision loss.
Adult Mouse Retina EV Characterization
Mouse retinal EV release rate and proteomic content was first analyzed. The data
revealed that adult mouse retina actively release EVs in situ at a rate of 1.42 +/- 0.08 x
108/ml over five days, with diameters ranging from 30nm-900nm. Mouse retina EV cargo
included mRNA associated with late retinal development and retinal function including
GPRC5b and Igsf8, the photopigment rhodopsin and neuronal nuclei marker NeuN. Next,
transfer of EVs between retinal cells was observed. Labeled retinal cell RNA was
encapsulated in lipid labeled EVs and imaged following uptake by co-cultured adult retinal
and retinal progenitor cells. Proteomic analysis of retina EV cargo revealed 1696 retinal
cell only, 957 shared retina and EV, and 82 EV only species. Retinal EV protein cargo
functions were strongly associated with RNA splicing (85.5%) and protein transport
(61.9%.). Data in this work indicates that the mouse adult retina releases EVs containing
genetic and molecular cargo reflecting the cell of origin expression state, that may be
transferred within the retinal microenvironment during normal and pathological states.
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Human Diabetic Retinopathy Retina EV Characterization in situ
Human non-diabetic and diabetic retinopathy retina and EV cargo were analyzed in situ.
Non-diabetic retinas were seen to release larger and more concentrated EVs. The
average size of EVs from non-diabetic retinas were 193.8 ± 6.52nm and diabetic retina
EVs were 157.5 ± 6.17. Average concentration of EVs released of non-diabetic retina was
1.62778 × 109 ± 1.69933 × 108 and from EVs released from diabetic retina 8.68556 × 10 8
± 1.56087 × 108. Biologic processes correlated to proteins in diabetic retina EVs strongly
associated with DR pathology and included carbohydrate signaling, wound healing, cell
proliferation and immune responses. Using FunRich miRNA enrichment tool we analyzed
the biological pathways of unique miRNA signatures associated with diabetic and nondiabetic retina EVs. We identified 301 miRNA signatures found between both samples,
there were 21 miRNAs present only in diabetic retina and 7 in non-diabetic retina. NGS
analysis of miRNA species found within diabetic retina EVs suggest a role in the
pathogenesis of DR.
Human Urine EV cargo from patients with Diabetic Retinopathy
We analyzed EVs from human urine normal, diabetic without DR, diabetic with mild DR
and diabetic with severe DR. Human non-diabetic urine EVs had an average size of
210.1nm ± 7.316, which was significantly smaller than diabetic DR urine EVs at 230.1nm
± 4.07. The average concentration of non-diabetic urine EVs was 4.63 x108 ± 4.20 x 107
and was significantly smaller than diabetic DR urine EV concentration at 6.83 x 108 ± 9.23
x 107. We analyzed the predicted biologic processes of DR urine EV cargo. The biological
pathways associated with severe DR urine EV proteins were mapped to DR pathways.
We found the top percentages to be metabolism (29.8%), diabetes (11.8%) and insulin
synthesis and processing (9.5%). These results suggest that proteins isolated from
severe DR urine EVs may be involved in the pathogenesis of DR.
Next, small RNA next-generation sequencing analysis was performed on EVs released
from non-diabetic (control) and diabetic retina in vitro. The analysis identified 301 miRNA
species shared between EVs from both samples, 21 species present only in diabetic
NPDR urine EVs and 7 only identified exclusively in non-diabetic control urine EVs. Next,
using FunRich miRNA enrichment software, enriched biological pathways associated with
diabetic or non-diabetic EV miRNA species were identified. There were no pathways
significantly enriched for the 7 miRNAs found only in non-diabetic EVs. Several pathways
were upregulated for diabetic EV miRNA species including endothelins (35.7%), VEGF
and VEGFR signaling network (36%) TRAIL signaling (37.1%), proteoglycan syndecan
mediated signaling events (37.4%) and plasma membrane estrogen receptor signaling
were significantly enriched (36.7%).

Comparison of In Situ Diabetic Retinopathy Human Retina EV cargo and Human
Urine EV cargo from patients with Diabetic Retinopathy
The next goal was to determine if retinal DR EV protein or miRNA signatures could be
detected in urine and provide information as a prognostic for DR onset or progression. 96
proteins were identified as present in both retina DR EV cargo and urine DR EV cargo.
The biological pathways correlated to the 96 shared proteins included metabolism
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(29.5%), integrin cell surface interactions (20.5%), VEGF signaling (18.2%), Arf6
signaling (18.2%), EGF receptor signaling (18.2%) and mTOR signaling pathway (18.2%)
each associated with DR pathogenesis. These results suggest that urine DR EV and
retina DR EV proteins may be helpful in detection of DR. Retina (tissue) EV miRNA was
compared to urine EV miRNA species to search for overlapping species. Comparison of
DR retina (tissue) EV miRNA only species (n=21) to NPDR urine EV miRNA only species
(n=15) showed no overlap. Next, expanded starting numbers of miRNAs compared total
DR retina (tissue) EV miRNAs (321) and total miRNAs present in NPDR urine EVs. With
this analysis, 13 shared miRNA species were identified (hsa-miR-485-5p, hsa-miR-323a3p, has miR-145-3p, hsa-miR-493-5p, hsa-miR-128-1-5p, hsa-miR-708-3p, hsa-miR485-3p, hsa-miR-130a-3p, hsa-miR-129-1-3p, hsa-miR-22-5p, hsa-miR-576-3p, hsamiR-548ba, hsa-miR-5187-5p). Using miRTarget link human database, these overlapping
urine EV miRNAs from NPDR and diabetic retina EVs are predicted to represent
pathways involved in DR.
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1. Neurodegeneration of the Retina

1.1. Anatomy and Functionality of the Mammalian Retina

The adult retina is an integral part of the central nervous system (CNS) and
approximately 55% of the cerebral cortex is allocated for visual processing.1 The complex
neural architecture found within the CNS is also evident in the design of the retina. The
human retina is approximately 0.3-0.5mm thick and lines the posterior portion of the eye.24

The major cell types in the retina include the Müller glia, rod and cone photoreceptors,

bipolar, amacrine, horizontal and ganglion neural cells3. The retina is layered into three
distinct nuclear lamina of neuronal cell bodies and two layers of synaptic networks known
as plexiform layers. 3-8 The photoreceptors are found in the outer nuclear layer (ONL) with
their synapses connecting with bipolar neuron synapses in the outer plexiform layer
(OPL). Within the inner nuclear layer (INL) we find horizontal, bipolar and amacrine nuclei
forming second order synapses in the inner plexiform layer (IPL), dorsal to the ganglion
cell layer (GCL) that contains the ganglion cell bodies and their axons, which form the
optic nerve. These cell types all play a role in the conversion of light stimuli into electrical
impulses that the occipital cortex detects and interprets as visual signals. Posterior to
and interdigitating with photoreceptor outer segments are phagocytic cuboidal
melanocytes known as the retinal pigment epithelium (RPE), that nourishes the eye and
removes waste materials. The RPE is critical to vitamin A metabolism and provides
structural support along with absorbing scattered light which greatly improves visual
acuity of the eye.5

1

The phototransduction of light within the mammalian retina is an elegant process. The
rod and cone photoreceptors are the two major retinal cell types converting photons of
light to electrical-chemical impulses that can be transmitted by the optic nerve to the
brain.5 There are on average 120 million rods and 5 million cones in the adult human
retina.7,9 The rods respond to low light (single photon) conditions and cones respond to
bright light at photon intensities that saturate rod responses. In general rods are
responsible for black and white vision while cones are responsible for color vision. This
however is an oversimplification as rods play a role in interpreting shape and structure
while cones are more responsible for acuity in our vision.

The nomenclature of rods and cones comes from the overall shape of their outer
segments which are composed of stacked discs of rhodopsin and opsin photopigments,
respectively.4,5,7 The pigments are responsible for phototransduction. In the rod cells the
protein rhodopsin is a 7-transmembrane domain with a covalently bound 11-cis retinal
molecule. As light hits the rhodopsin molecule it converts the confirmation of 11-cis retinal
to all-trans-retinal. This new confirmation of all-trans-retinal detaches from rhodopsin due
to its lower binding affinity and activates the G protein tranducin. In its active form
transducin then activates the enzyme phosphodiesterase (PDE) which hydrolyzes the
secondary messenger cyclic guanosine monophosphate (cGMP) to guanosine
monophosphate. As these levels of cGMP are diminished, they cause Na+ ion channels
to close and result in hyperpolarization of the cell, confirmation which causes a reduction
in the release of neurotransmitters such as

2

glutamate.

5,10-13

This unique phenomenon in the retina has an antagonistic effect with

bipolar cells. These bipolar cells have on-off phenotypes which can detect and respond
to rod and cone cell signaling.8,14,15

The mechanistic process of phototransduction in rods is similar in cones. The difference
between rods and cones, beyond their shape and numbers are the pigments present
within the cell. Cone cells, which are much more sensitive to bright lights and color,
contain three different kinds of light sensitive pigments.15-17 These proteins, while similar,
contain different sequences of amino acids which give them different light sensing
properties. There are three main cone subtypes with photopigments that respond to either
short, medium or long wavelengths in the visible light spectrum. Cones respond to
wavelengths in the range of 420nm to 560nm detecting red (564nm), green (533nm) or
blue (437nm)18. The way our brain interprets color is the compilation of cones being
excited by different wavelengths of light.

The distribution of photoreceptors within the retina is directly linked to functionality. Rods
outnumber cones with a ratio of about 20:1 and they are dispersed primarily within the
periphery of the human retina.
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The central foveal region of the retina has the highest

concentration of cones. Foveal architecture forms a pit like depression containing only
small, tightly clustered cones allowing for processing of visual signals with highest
acuity.3,20 The depression is due to the decrease in the other cell types and nerve bundles
which limits the distortion of light that interacts with cones unobstructed. Moving from the
fovea towards the periphery there is an exponential increase in rod cells with pockets of
cone cells throughout. The peripheral region has an abundance of singular ganglion cells
connected to multiples of photoreceptors. This design makes the periphery of the retina
3

more sensitive to light but with diminished acuity.

15,21

Moving closer to the center of the

retina there is a lower proportion of ganglion cells to photoreceptors which boosts visual
acuity dramatically.

Beyond the photoreceptors there are several types of cells within the retina that are crucial
to its functionality. There are parallel pathways within the neural retina for signals to travel
from the photoreceptor layer to the GCL. The most direct path is from the photoreceptors
to bipolar cells, then to the ganglion cells, however, there are horizontal cells and
amacrine cells in the outer nuclear layer and inner nuclear layer, respectively, that
process impulses from photoreceptors to ganglion cells.5,6,21 Horizontal and amacrine
cells vary in subtypes and morphology. Horizontal cells connect laterally with rod and
cone synapses, propagating impulses towards bipolar cells. Because amacrines receive
input from several different photoreceptors, they function in filtering out weak signals and
send stronger signals.3,4,7 Amacrines are involved in regulating transmission with bipolar
cells. Many amacrine cells are inhibitory and use GABAergic neurotransmitters to
modulate the intensity and temporal patterning of signals to generate efficient impulses
that can be sent to the GCL.

1.2. Neurodegenerative Diseases of the Retina

1.2.1. Age Related Macular Degeneration
Age Related Macular Degeneration (AMD) causes severe visual impairment currently in
approximately 8 million Americans and is expected to affect 196 million individuals
4

worldwide by 2020.22,23 It primarily affects individuals over the age of 45 and is more
common in female and lightly pigmented individuals.24 AMD causes vision deterioration
primarily through damage to the macular region of the retina, an area responsible for
highest visual acuity. There are two main forms of AMD classed as wet and dry with
distinctive pathological features that make them unique.

The first stages of AMD typically develop with the appearance of a material known as
drusen, which is an accumulation of lipids, salts and components of the extracellular
matrix that are deposited beneath the retina.25-27 The appearance of hard drusen is part
of the natural aging process and does not indicate disease, however in early stages of
AMD there is an accumulation of “soft” drusen. The difference between hard and soft
drusen is their level of distinctive edges; hard drusen has pronounced margins while soft
drusen has non-distinct margins. The appearance of excessive amounts of soft drusen is
a hallmark of AMD, and their abundance determines the severity of AMD.

The accumulation of soft drusen within the eye indicates advanced stages of AMD.
Drusen is deposited under the retina typically between the RPE layer and Bruch’s
membrane. Bruch’s membrane is a laminated structure adjacent to the choroid layer
within the retina.28 This structure is essential for nourishment and metabolite exchange
between the RPE and the vascular choroid layer. With aging, the elasticity and
permeability of Bruch’s membrane is affected which impedes its ability to effectively
transport substances across these layers.22,26,29 Drusen is gradually built up in the Bruch’s
membrane and distorts the functionality of the RPE. This leads to an increase in
inflammatory stress responses from activated microglia that increase oxidative species
and inflammatory cytokines and causes progressive dysfunction of the RPE integrity. The
5

RPE is a central regulator of photoreceptor health and functionality and impairment to this
layer can drastically affect the retina and visual acuity.

The pathogenesis of early/intermediate AMD includes geographic atrophy (GA) involving
the accumulation of drusen, inflammatory response and RPE/Bruch’s membrane
malfunction leading to degeneration of the RPE and retinal layers including
photoreceptors.22,27 AMD related GA accounts for approximately 20% of all legal cases
of blindness in North America. Complete central vision loss through GA is caused by
involvement of the macular area of the retina; GA in the periphery causes minor visual
impairments such as blurriness, scotomas and light sensitivity. RPE detachment is a
characteristic of advanced AMD in which there is buildup of fluid between the
RPE/Bruch’s membrane.29,30 Detachment of the RPE from the choroid layer leads to
death of the RPE cells with resultant improper regulation of metabolites and waste
products from the adjacent retinal cell layer. Advanced GA may involve choroidal
neovascularization (CNV) which is characterized by the growth of new blood vessels
originating from the choroid layer that extend beyond Bruch’s membrane through the
photoreceptor layer resulting in retinal detachment and vision loss.27,29 There are several
molecular mechanisms which lead to CNV, including inflammation and cell senescence,
however, the key mechanisms is a dysregulation of vascular endothelial growth factor
(VEGF).

11,25.

This works in opposition with pigment epithelium derived factor (PEDF) to

control growth of blood vessels within the choroid, an overexpression on VEGF or
decreased production of PEDF leads to growth of new blood vessels. These new blood
vessels are brittle, leaky and result in scarring of the macula.

6

There are several treatment options for the various conditions associated with AMD. The
initial approach is to address risk factors such as smoking and high fat diet that have been
associated with increased risk of AMD.31-33 For more severe conditions such as CNV
there are intravitreal injections of antiangiogenic drugs such as anti-VEGF agonists that
limit angiogenesis. Similarly, antibody-mediated treatments like ranibizumab and
bevacizumab have been developed to inhibit VEGF by binding to it with high affinity.26,29,33
AMD is a multifactorial disease involving oxidative stress and inflammatory pathways.
Two drugs, Resveratrol and alpha-lipoic acid, are treatment options that may help to
reduce the apoptotic environment seen with AMD.34-36 These treatments act by limiting
oxidative stress through MAPK/ERK pathway or through mitochondrial dehydrogenase.
They act as free radical scavengers that limit the effects of this inflammatory network.
Other forms of treatment include photocoagulation and photodynamic therapy, even
though their use has been reduced in recent times.37 New interventions such as stem cell
therapy utilize stem cell derived RPE cells for transplantation to help preserve retinal
function. 38-40

1.2.2.

Glaucoma

Glaucoma is a group of conditions frequently associated with dysregulation of intraocular
pressure which ultimately damages the optic nerve. There are sophisticated drainage
systems within the eye that regulate the flow of aqueous humor within the trabecular
meshwork and uveoscleral outflow pathway.41-43 Glaucoma is one of the leading causes
of visual impairment and blindness, affecting approximately 70 million people globally with
3 million in the US alone.41,44 Glaucoma can be divided into two general classes: primary
open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG) with POAG
being the more common and chronic and PACG being the more acute and urgent.
7

To fully understand these two conditions, we have to analyze the normal drainage system
within the eye. The aqueous humor is a fluid produced by the ciliary body within the eye.
It functions primarily in nourishing the eye with essential nutrients and proteins, but also
regulates ocular pressure and shape. 45 The aqueous humor flows between the anterior
and posterior chambers of the eye circulating among the iris, pupil and cornea. As fluid is
produced by the ciliary body it travels through the pupil, and then is drains through the
trabecular meshwork. The consistent flow of the fluid within the eye maintains a safe
pressure that allows the eye to function; any changes in this equilibrium can lead to
glaucoma.

In POAG the drainage of aqueous humor through the trabecular meshwork is usually
diminished. This reduction can be due to an array of factors including structural changes
to the trabecular meshwork or obstructions to the flow.46,47 Within the eye the GCL is
bundled into a continuous tract that forms the optic nerve in the posterior portion of the
eye. This bundle of axons is responsible for transmitting impulses from the retina to the
CNS. Increased resistance present in POAG puts stress on the GCL, limiting axonal
transport through the mechanical stress leading to optic nerve damage involving
inflammatory responses, neurotoxicity and apoptosis.41-43,46,48-50 The stress placed on the
GCL creates a cascade of events that eventually lead to degeneration of retinal ganglion
cell axons and the optic nerve.

In PACG, there is closure of the angle between the iris and the cornea. Individuals with
PACG have a shallower anterior chamber, increased lens thickness and crowded anterior
segment.41,51,52 The mechanisms that lead to the development of PACG tend to be
8

pupillary block, plateau iris syndrome, lens disproportion, and ciliary block. The most
common mechanism that causes PACG is pupillary block, caused by the iris moving
posteriorly, obstructing the fluid flow to the anterior chamber. The change in pressure
between the anterior and posterior chamber of the eye leads to an upward shift of the iris
and obstructs drainage of the trabecular meshwork. 51,52

The diagnosis of glaucoma involves measuring intraocular pressure, typically as a first
step, but 50% of patients with glaucoma have normal readings of intraocular pressure
(10-21mm Hg).41,43 most individuals are unaware of glaucoma in the early stages as they
are asymptomatic; symptoms (i.e. vision loss) is not present until the disease has
progressed to a chronic state.

For accurate diagnosis, a series of tests must be

performed including visual field testing, Optical coherence tomography (OCT), analysis
of cup disk ratio (CDR) and standard measurement of intraocular pressure using
tonometry43,52-54

Therapies for glaucoma include target lowering intraocular pressure to effectively manage
the disease.54-57 Several treatments in the form of eye drops have been approved to treat
glaucoma by either decreasing aqueous production or increasing the flow of aqueous
humor through the eyes’ drainage systems. The first line of treatment is typically a
prostaglandin analog that works by increasing uveoscleral and/or trabecular outflow.55
Other classes of drugs used to treat glaucoma are beta-blockers, alpha-agonists,
carbonic anhydrase inhibitors and cholinergic agents. Cholinergics use the same
mechanism as prostogladin analogs to increase the flow of aqueous humor while betablockers, alpha-agonists and carbonic anhydrase inhibitors work by decreasing the
production of aqueous humor.41,43,50,54,57,58
9

1.2.3. Diabetic Retinopathy
Diabetic Retinopathy (DR) is a neurovascular complication associated with diabetes
mellitus that currently

affects approximately 120 million people worldwide and its

prevalence is expected to reach 190 million by 2030.59 The complications associated with
diabetes mellitus including hyperglycemia and hyperlipidemia, create a state of chronic
inflammation negatively affecting tissues systemically.

60

More specifically, in the retina

there is increased metabolic demand, creating a high level of metabolic end products that
must be managed correctly and any imbalance can create a detrimental environment.61
In the chronic state of diabetes this affects the functionality of the retina by compromising
its vasculature integrity which then creates adverse effects to the neural component.
Here, we will discuss the pathophysiology of DR, and the different conditions associated
with it.

The first risk factor for DR is uncontrolled levels of sugar in the blood, due to a lack of
insulin, or impaired insulin sensitivity leading to hyperglycemia. This then creates a
cascade of events that contributes to the development of DR. Hyperglycemia stimulates
the production of reactive oxygen species (ROS) in adipocytes and is one of the first
stages in the dysregulation of blood vessel integrity.

62

Additionally, molecules such as advanced glycosylation end products (AGE), are formed
from hyperglycemia, and increase oxidative stress and inflammation. AGEs affect retinal
vascular integrity by crosslinking to proteins within the basement membrane, and as a
result there is increased vascular permeability, Protein kinase C (PKC) activation and
adhesion molecule expression. 63-66
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These processes contribute to development of DR at different levels of severity. The two
main forms are non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic
retinopathy (PDR). NPDR can be further classified as mild, moderate or severe based on
the level of progression of the disease. The visible progression of NPDR begins with the
formation of microaneurysms, areas within capillary that develop due to damage to the
tunica intima wall of the vessels. Weakened vessel integrity and connective proteins lead
to obstruction in normal blood flow, dilation and leakage. The observation of
microaneursyms is a standard diagnostic marker of mild NPDR.

During NPDR

pathogenesis fluid leakage containing precipitates of lipid and protein clusters indicates
a shift to moderate NPDR. Other hallmarks of moderate NPDR include capillary
hemorrhaging, venous beading and the presence of cotton wool spots. 67-70 In severe
NPDR the findings include more than 20 intra-retinal hemorrhages in each of 4 quadrants,
venous beading in 2 or more quadrants or intraretinal microvascular abnormalities
(IRMAs) which are growth or branching of capillary networks in one or more quadrant but
not proliferative diabetic retinopathy.71,72
The more severe forms of DR involve proliferation of new blood vessels due to
dysregulation of the endothelial cells lining blood vessels, vessels in DR can have dueling
phenotypes of hyperperfusion and hypoperfusion.

73

The latter leads to ischemia within

the eye and triggers the release of inflammatory chemokines. Hypoperfusion is caused
by a cascade of events that begins with the inflammatory response of hyperglycemia.
This results in an immune-targeted response by microglia within the retina and circulating
monocytes that rush to the inflamed site. These chronic conditions lead to loss of
endothelial cells and pericytes, further compromising vessel permeability. One immune
response that diminishes permeability is leukostatis, in which leukocytes form complexes
11

with dysfunctional endothelial cells and surrounding materials, creating an ischemic locale
due to the diminished permeability.43,74 In this ischemic state, the retinal environment
secretes a host of growth and inflammatory factors. The most prominent is VEGF which
stimulates the growth of new blood vessels and creates the proliferative form of DR. Other
factors that contribute to angiogenesis of the retina include erythropoietin and insulin
growth factor.67,70,72 PDR can cause vision loss by contributing to macular edema and
retinal detachment. Also, the new blood vessels are brittle and leaky, growing on the
surface of the retina. Repeated hemorrhaging of these vessels leads to fibrosis, gliosis
and fibrovascular scaring that tugs on the retina causing retinal detachment and potential
vision loss.

67,74,75

The early stages of DR are typically asymptomatic: if the disease goes untreated,
irreversible damage can be done to the retina. Diagnosis of DR is established by an
ophthalmoscopic examination and detection of changes in the normal structure and
vasculature of the eye.

Beyond DR associated damage to retinal vasculature there is also significant
degeneration of the neural retina that is hard to detect despite many researchers believing
neuronal damage occurs first. Neurodegeneration in the diabetic retina is triggered by
reactive metabolites and hyperglycemic conditions that lead to mitochondrial dysfunction,
the production of ROS, neuronal apoptosis, glutamate excitotoxicity, glial cell activation
and loss in synaptic activity. 74 Through OCT and histological studies, it has been shown
that there is decreased thickness in the nerve fiber layer due to loss of RGCs, which are
one of the first neural cell types to be affected by DR.

76-78

RGC loss may be caused by

the activation of Müller cells and the upregulation of GFAP which activates
12

proinflammatory cytokine networks. In DR, the upregulation of VEGF is a trigger for gliosis
and a possible mechanism of Müller cell activation and consequent inflammatory
responses which lead to neuronal apoptosis.

79-81

Müller cells are also responsible for

neurotransmitter uptake and play a key role in regulating glutamate and K + ions. During
DR pathogenesis Müller cells show a significant decrease in the Glutamate Aspartate
Transporter (GLAST) leading to increases in toxic synaptic glutamate levels.
Photoreceptor loss is another characteristic of early DR. Photoreceptor loss has been
correlated to decrease in the neuroprotective proteins somatostatin, corticostatin, and
pigment epithelium-derived factors and increases in pro-apoptotic proteins such as Bax
and cytochrome c. 82-84 Recent studies have shown that photoreceptors contribute to DR
pathogenesis by increasing hypoxia and oxidative stress as a result of their increased
oxygen consumption and increased production of superoxides.85-88

There are several treatments for DR based on the level of disease progression. The
primary therapy is controlling glycemic concentration. If an individual with diabetes does
not effectively regulate their blood sugar the progression of DR will worsen over time. In
the early stages of DR such as NPDR there may not be a need for intervention and
regulating blood sugar levels could be enough to limit progression of the disease. In
advanced stages, there are therapies designed to treat the underlying pathology. Similar,
to wet-AMD, administering anti-VEGF compounds, through intravitreal injections, inhibit
angiogenic events in the retina and may reduce swelling in the macula. Other therapies
include photocoagulation that targets healthy retina vessels to reduce overall metabolic
demand. In severe PDR, vitrectomy may be performed to remove excess blood, fibrous
proliferation and fluid from the vitreous. 67,72,74,89,90
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2. Extracellular Vesicles

2.1. Exosome and Microvesicle Genesis and Content
Exosomes and microvesicles, are lipid enclosed cell fragments with diameters ranging
from 50nm to 2m and released from most cell types including embryonic stem cells,
hematopoietic stems, neurons and malignant cells

91-94

. Exosomes have diameters of

30-130nm and are formed through the endosomal-sorting complex required for transport
(ESCRT)95. The formation of exosomes occurs through three primary processes: 1)
initiation or early endosome formation, 2) multivesicular body (MVB) formation and 3)
exosome secretion. The initial stage of exosome formation involves invagination of the
plasma membrane where vesicles are targeted to early endosomes. Within the ESCRT
system endosomes and intraluminal vesicles are formed at MVBs and either transported
to lysosomes for degradation or exocytosed through the plasma membrane via calcium
dependent mechanisms, as exosomes

96-99.

Canonical markers for exosomes include

tetraspanins and plasma membrane proteins such as CD9, CD63, Alix, PIP3 and TSG101
95.

Microvesicles are heterogeneous in size with diameters from 100-2000nm. While
exosomes fall within the size range of microvesicles, microvesicles are distinct in
formation, secretion and content

100-102.

The formation of microvesicles involves

interactions between cytoskeletal and phospholipid proteins of the plasma membrane
101,102.

Microvesicle formation occurs via evagination of the plasma membrane facilitated

by transferases that interact with phosphatidylserine proteins, leading to vesicle
translocation onto the outer membrane leaflet. The contraction of actin-myosin filaments
within the cytoskeleton completes the budding process, releasing microvesicles into the
14

extracellular space

103,104.

Established markers for microvesicles include integrins and

selectins such as B1 and CD62 and membrane proteins such as CD40

95.

Exosomes and microvesicles have been shown to be involved in cell-cell communication
via transfer of proteins, mRNA, miRNA and DNA

105,106.

Exosomes and microvesicles

encapsulate factors representative of cell of origin genotype and phenotype. Exosome
and microvesicle encapsulated factors have been shown to be involved in tumor
progression that promote extracellular matrix degradation, angiogenesis, proliferation and
immune avoidance

93,107,108

. Active molecules in tumor cell microvesicles include

proteases, that degrade extracellular matrix, VEGF, a canonical angiogenic, epidermal
growth factor protein (EGF and its receptor (EGFR) which are involved in cell proliferation
109,110.

The activity of microvesicles in tumor cell proliferation, survival and metastasis is

one example of the cell specific biological significance of microvesicle content and
function.

Within the nervous system exosomes and microvesicles have been shown to be involved
in developmental processes, nerve regeneration, synaptic activity and even
neuroprotection 111,112. Studies by Ratajczak et al. have shown that microvesicles derived
from embryonic stem cells (ES-MV) are able to modulate the self-renewal capacity of
hematopoietic progenitor cells by horizontal transfer of mRNA

113.

Upregulation in

transcription factors such as Oct-4, Nanog and Rex-1 suggest that ES-MVs are able to
modulate surface receptor and transcription factor expression as a method of increasing
pluripotency within these cells. Microvesicles have also been shown to be involved in
healthy nervous system function by reducing inflammation, protecting cells from stress
and reducing toxic environments 114-116.
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2.2. Exosomes and Microvesicles as Biomarkers
Biomarker based early diagnosis and therapeutic intervention are key goals in a growing
number of disease management strategies 91,106. A biomarker is a measurable substance
present in the body that can be used to identify health, pathogenic processes and
pharmacological responses

117.

Exosomal, microvesicle and circulating miRNA

biomarkers are currently being explored to help monitor disease predisposition,
pathogenesis and response to treatment

91,108,118,119.

The cell state specific molecular

content of exosomes and microvesicles released from disease cell populations can be
characterized for development as novel biomarkers. Exosomes and microvesicles,
released from organ tissues, circulate systemically and once isolated can be analyzed for
molecular content to identify a range of diseases 105,120-124. Exosomes and microvesicles
have been characterized from several pathologies including neurodegenerative disease,
cancer, cardiovascular disease and disorders of the immune system

91,106,108,119,125,126.

Circulating exosomes and microvesicles can be isolated from most biological fluids
including saliva, blood, urine, vitreous and cerebral spinal fluid

99,106,118,124.

Currently efforts by Melo et al. have discovered a specific molecular signature for some
cancer in exosomes isolated from patients

127.

Glypican-1 (GPC1), a membrane protein,

is overexpressed in breast and pancreatic cancer and was used as a target exosome
encapsulated molecule for cancer detection. Circulating exosomes isolated from serum
of mice and human patients with cancer were screened using this GPC1 marker. Their
results showed that GPC1 was more abundant within the circulating exosomes of cancer
subjects compared to normal. More importantly they showed that GPC1 within exosomes
can be used for early cancer detection. Patients with histologically validated pancreatic
cancer precursor lesions and benign pancreatic disease had higher levels GPC1 within
16

exosomes when compared to controls. This work suggests that exosome biomarkers can
be used as a diagnostic early pre-clinical disease pathogenesis.

Of central importance of analysis described in this work is the identification of exosome
and microvesicle biomarkers for diseases of the nervous system, specifically of the neural
retina. Often in neurologic diseases diagnostic symptoms appear in the later stages of
disease progression. This limits the ability for therapeutic intervention to halt disease
progression at an early stage. Extracellular vesicles are currently being investigated as
biomarkers for several diseases affecting the CNS including Parkinson’s Disease, AgeRelated Macular Degeneration and Alzheimer’s Disease.

2.3. Extracellular Vesicles in the CNS

2.3.1. Extracellular Vesicles identified in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disease that primarily affects individuals
over the age of 65. A diagnostic feature is loss of motor control resulting from neural
degeneration in the substantia nigra pars compacta

128.

The disease affects primarily

dopaminergic neurons and malfunctioning leads to severe motor deficiencies with
progression to dementia. Degeneration of dopaminergic neurotoxicity, release of ROS
species and consequent oxidative damage 117,128 Neural dysregulation in PD leads to the
overexpression of α-synuclein, parkin, DJ-1 and superoxides, each involved in disease
progression

128.

A recent study showed that exosomes isolated from the urine of male

patients with PD have significantly higher levels of DJ-1 compared to age-matched
controls 122. The study concluded that exosomes of PD patients have increased levels of
DJ-1 which may be used as a diagnostic marker of PD. Similarly, a separate study
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analyzed exosomes isolated from the urine of PD patients’ and detected high levels of αsynuclein compared to controls. Exosome release was also seen to be regulated by
PARK9/ATP13A2, an ATPase transporter involved in ion transport, including Zn 2+,
required for the compartmentalization of α-synuclein in exosomes

129.

By understanding

the regulation of exosomal α-synuclein packaging and release, strategies for PD
detection and response to treatment can be developed.

2.3.2. Extracellular Vesicles identified in Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by accumulation
of amyloid beta (AB) plaques, as well as neurofibrillary tangles of hyperphosphorylated
tau protein in the cortex and hippocampus

130.

Despite advances in imaging and genetic

testing there remains a need for biomarkers to facilitate early detection of AD

131.

New

evidence suggests that exosomes contain tau and AB, which are involved in disease
progression

132,133.

Tau containing exosomes have been shown to be detectable in CSF

during early AD onset 121. Extracellular AB has also been shown to be regulated through
exosome compartmentalization and release. Dinkins et al., found that AB enriched
exosomes injected into 5XFAD mice (a murine AD model) caused increased aggregation
of plaques and neuronal death 134. They also showed that by blocking nSMase2 with the
inhibitor GW4869, a regulator of exosome formation, plaque formation could be reduced.
This suggests a key role of exosomes in plaque formation but also points to nSMase2 as
a novel therapeutic target

134.

Interestingly, Yuyama et al. showed a protective effect of

healthy neuronal exosomes in an AD disease model.

Healthy neuronal exosomes

injected intercerebrally in APP transgenic mice were observed to decrease the formation
of AB deposition via AB sequestration. Overall these findings suggest a role for neural
exosomes in neuroprotection, disease pathogenesis and biomarker discovery 135.
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2.4. Extracellular Vesicles in Retina Neurodegenerative Diseases

2.4.1. Extracellular Vesicles identified in Age Related Macular Degeneration
A recent study of an AMD mouse model has identified molecules upregulated in diseased
vs. normal retina

136,137.

They used RPE dysregulation to simulate AMD using retonone

to cause mitochondrial stress. They found that there was increased expression of
mitochondrial damage and autophagy markers such as Autophagy Protein 12-Autophagy
Protein 5 (Atg12-Atg5). Also, the RPE of diseased eyes exhibited higher microvesicle
release rates with increased expression of CD63 and LMP2. RPE exosomes were
collected from culture medium and isolated using ultracentrifugation. Analysis revealed
the presence of drusen inside exosomes, suggesting involvement of exosomes in drusen
formation138,139. Similarly, eotaxin-2, involved in chronic inflammation, was identified in
exosomes at significant levels in AMD patients 140-142. Importantly, a set of miRNAs (hsamir-301-3p, hsa-mir-361-5p, and hsa-mir-451a-5p) was shown to be transferred between
exosomes in blood plasma of AMD patients 93,143. These circulating miRNAs interact with
complement factor H which is a key regulator inflammatory responses. Polymorphisms
within the complement factor H gene region is linked to an increased risk of AMD. Also,
proteomic analysis of exosomes isolated from the aqueous humor in patients with AMD
contained high levels of proteins involved in neovascularization and inflammation144. The
authors concluded that the increased exosomal protein content found within their AMD
patients will play a key role in developing new biomarkers and therapeutic techniques.
2.4.2. Extracellular Vesicles identified in Diabetic Retinopathy
As described above, DR pathogenesis involves number of probable pathogenic pathways
including increased blood glucose levels, glutamate toxicity and degeneration of retinal
tissue

145.

Approximately one third of people suffering from diabetes also have diabetic
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retinopathy. Diabetes induced damage to retinal blood vessels causes the production of
pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α leading to inflammatory
processes and necrosis 146,147. Exosomes isolated from retinal astroglia and injected into
the retinal environment have been found to limit DR neovascularization by reducing the
number of migrating microvascular endothelial cells and delivering anti-angiogenic
protein cargo. Anti-angiogenic molecules identified in astroglia exosomes include
endostatin, macrophage inflammatory protein-1, tissue inhibitor of metalloproteinases.148
Researchers Porta et al. also identified EVs found in the serum of DR patients and found
that miRNAs miR-150-5p, miR-21-3p and miR-30b-5p were upregulated in DR patients
vs healthy control and were shown to function in vessel formation, endothelial cell
migration and vascular permeability.149
The development of extracellular vesicle biomarkers for early detection of retinal
disease offers promise for early intervention and reduction of disease progression. The
work presented in this study focuses specifically on characterizing exosomes and
microvesicles released from Diabetic retinal tissue to contribute to the tools available for
biomedical approaches to diagnosing and tracking response to treatment in retinal
disease.

3. Extracellular Vesicles in the Adult Mouse Retina
3.1. Introduction
The mammalian retina releases a range of extracellular soluble factors active in
developmental processes, adult physiology and neuroprotection150-152 Established
soluble factors present during retinal development, involved in cell division and fate
determination include basic fibroblast growth (bFGF), transforming growth factor (TGF)20

a, and leukemia inhibitory factor (LIF). In the adult retina, a number of neurotrophic factors
are released from Müller glia including ciliary neurotrophic factor (CNTF) and brainderived neurotrophic factor (BDNF)152. In this work, we begin to define a novel form of
diffusible retinal signaling by characterizing the release kinetics, ultrastructure and
molecular content of extracellular vesicles (EVs) released in the adult retinal
microenvironment.

3.2. Characterization of Extracellular Vesicles from mouse retina
Concentration and diameter ranges of EVs released from adult mouse retina in culture
were characterized using Nanosight analysis. Still images from Nanosight laser diffraction
videos show greater numbers of EVs suspended in retina-conditioned media (Figure 1b),
compared to control media (Figure 1a). Raw data traces of retina EVs and control show
intrinsic sample variation and size distribution (Figure 1c, d) respectively. Nanoparticle
Tracking Analysis (NTA) revealed a significant increase in retina released EVs (1.42 +/0.08 x 108 / ml) compared to control (0.15 +/- 0.09 x 108) (p=0.0097) (Figure 1e). The data
indicates that, in the defined culture conditions at 37°C, individual retina release
approximately 1042.00 EVs per hour.
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Figure 1. Retinal EV release rate and
diameter range
Nanosight laser diffraction analysis of
individual EVs in single frames of
tracking for a) control media and b)
retina-conditioned
media.
c)
Concentration and diameter traces
from d) retina-conditioned media and c)
control media reveal intrinsic variation
in concentration and range of
diameters. e) Nanoparticle Tracking
Analysis (NTA) revealed a significant
increase in retina released EVs (1.42
+/- 0.08 x 108 / ml) compared to control
(0.15 +/- 0.09 x 108) (p=0.0097
student’s t-test n=3). f) NTA analysis
revealed a significant difference in
mean diameter of EVs released from
adult retina, 202 +/- 21.7 nm, compared
to control 120 +/- 9.9 nm (p= 0.0389
student’s t-test n=3). g) EVs released
from retina contained a heterogeneous
population of particles ranging from 10910nm in diameter. Retinal samples
have unique sizes within the 410 to
910nm range. h) At each diameter
analyzed retina EVs exhibited higher
concentrations.

NTA analysis also revealed a significant difference in mean diameter of EVs released
from adult retina, 202 +/- 21.7 nm, compared to a control media 120 +/- 9.9 nm (Figures
1f) (p= 0.0389). Retina EVs had a broader total diameter range of 10-910nm, compared
to a range of 30-400nm for controls (Figure 1g, h). In the upper range, retina EV diameters
at 710nm, 810nm and 910nm had concentrations of 0.015 x 106/ml 0.01067 x 106/ml
0.00017 x 106/ml, respectively. Table 1 shows a summary of the NTA analysis highlighting
observed features in retina EVs.
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3.3. Transmembrane proteins and morphology of retinal extracellular vesicles
To further validate the presence
of EVs within samples, isolated
EVs

were

analyzed

immunogold
Figure 2. Immunogold EM analysis of retinal EV
ultrastructure and protein localization Immunogold TEM
analysis of EVs released from adult retina show positive
labeling for canonical markers of both exosomes and
microvesicles. a) The MVB synthesis protein, tumor
susceptibility gene 101 protein (TSG 101) and b) the
transmembrane extracellular protein CD63, both exhibited
positive labeling on EVs. c) control with no labeling. Scale:
100nm

TEM

using
against

established EV markers (Figure
2). Two canonical EV markers
used, which label both exosomes
and

microvesicles,

were

the

multivesicular body (MVB) synthesis protein, tumor susceptibility gene 101 protein
(Tsg101) (Figure 2a) and
the

tetraspan

protein

CD63 (Figure 2b). EVs
labeled for both markers
and

negative

showed

control

no

labeling

(Figure 2c). Retina EVs
Figure 3. Retinal EV protein and mRNA content
A) Western blot analysis of equal amounts of protein analyzed from
retina and EVs reveals CD63 concentrated in the EV sample. b) CD63
protein band intensity quantification shows higher levels of CD63 in the
EV sample compared to the same volume of retinal protein and c) the
intensity quantification for beta-actin shows higher levels in the retina
compared to the same volume of EV protein. d) qPCR analysis shows
retina and EV expression levels of transcripts associated with neural
differentiation and organization including GPRC5b, Igsf8. Smoc1 was
found in retina but not detected in EVs. e) Adult retinal and neuronal
markers were present in both retina and EVs including rhodopsin and
Neun. Recoverin was only detected in retinal cells.

analyzed

using

TEM

appeared on average to
exhibit

spheroid

morphologies, supporting
characterization
exosomes

as
and

microparticles 100,153.
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3.4. Molecular content of retinal extracellular vesicles
The molecular content of retina
EVs was analyzed and compared
to adult retina of origin at RNA and
protein levels. At the EV marker
level, TEM results showed colocalization of CD63 to the EV lipid
wall.
Figure 4. Lipid membrane and RNA labeled EVs released
from adult retina are up-taken by unlabeled retinal cells
Super-resolution microscopy was used to visualize RNA
(SytoRNA/green) and lipid membrane (PKH26/red) labeled
EVs released from adult retina and taken up by control nonlabeled adult retinal cells in a transfer experiment. Adult
retinal cell with internalized EVs imaged for transferred A)
total RNA (FITC/green) and B) lipid membrane (TRITC/red)
with nuclei labeled with (DAPI) following transfer of EVs. D)
Overlay reveals co-localization of transferred EVs with visible
RNA and lipid membrane within the proximity of the
perinuclear envelope of receiving retinal cell.

The

validated

concentration
using

Western

was
blot,

which revealed the EV marker
CD63 at higher levels in EVs
relative to retina (Figure 3a-c).
Next, total RNA was isolated from
retina and EVs for qPCR analysis.

Target genes selected for RNA analysis were identified from recent retinal progenitor cell
EV analysis and associated with retinal organization and function 154-156. We analyzed EV
cargo for the presence of SPARC related modular calcium binding 1 (Smoc-1), G proteincoupled receptor 5b (Gprc5b) and immunoglobulin superfamily member 8 (Igsf8) using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control (Figure 3d). Smoc-1
has been shown to localize to Müller cells during retinal development and function as a
calcium binding protein in pericellular matrices

157,158.

Igsf8 is an immunoglobulin protein

that binds tetraspanin molecules and regulates synapse structure through CD9 cell
adhesion molecules

155.

Gprc5b is associated with retinal development and physiology

through interaction with retinoic acid signaling pathways

159-161.

This initial gene

expression analysis revealed that retinal EVs contain Gprc5b and Igsf8 mRNA (Figure
24

3d). The expression
levels

observed

retina

in

were

comparable
levels,

to

with

EV
the

exception that Smoc1
while present in retina
was not detected in
EVs.

Figure 5. Retinal EV’s share similar proteins with parent retina tissue.
A) Venn diagram showing distribution of over 2500 proteins identified in
retinal samples (n=2). Of the proteins identified 957 were present in both
retina tissue and EV. 1696 were found only in retina and 82 unique proteins
were identified within EV’s. B) Venn diagram showing top biological
processes associated with EV proteins only (82) released from mouse
retina C) Chart showing percentages of different molecular processes
associated with proteins identified only in EVs. D) Table showing top
categories and number of EV proteins in EVs (82) and those shared with
retina (954). Darker blues in D) indicate greater numbers of EV proteins
associated with each biologic process.

In

addition

analyzing

for

organization

to
retinal

markers

present in EVs, qPCR
was
detect

performed
transcripts

to
of

established markers of retinal neural identity and function, rhodopsin, recoverin and the
RNA Binding Protein Fox-1 Homolog 3 (Neun) (Figure 3e). Rhodopsin is the photoresponsive, G-coupled receptor of rod cells, of which there are approximately 6.4 million
in each mouse retina162. Recoverin is a calcium binding protein involved in modulation of
phototransduction in rods and cones163. Recoverin also localizes to a percentage of cone
bipolar interneurons164. Neun is a nuclear protein localized to retinal ganglion and
amacrine cells165. The predicted function of Neun is as an RNA binding protein involved
in regulation of splicing166. Analysis revealed the presence of rhodopsin and Neun in EVs,
while recoverin was detected only in retina.
25

To visualize potential genetic cargo transfer by EVs in the adult retinal microenvironment,
we imaged EVs released from adult retina with labeled total RNA (SytoRNA/green) and
lipid membrane (red). Labeled adult retina released FITC RNA cargo within TRITC lipid
enclosed EVs through transwell pores and the uptake of these EVs were visualized in
control non-labeled adult retinal cells in lower wells using super-resolution microscopy
(Figure 4). Following five days of transfer labeled EVs (green RNA and red lipid
membrane) were observed localized within the cytoplasm, often close to the nuclear
membrane, within receiving adult retinal cells.

3.5. Proteomic analysis of retina and EV cargo
LC-MS analysis was performed on retinal tissue and EVs to characterize protein species
across both samples. Proteomic analysis identified a total of 2735 proteins present across
retina alone (1696), retina and EVs (957) and EVs alone (82) (Figure 5A). Bioinformatics
analysis was then performed to model the role EV proteins are predicted to be involved
with in the adult retinal microenvironment. The bioinformatics and network mapping
software FUNRICH was utilized to analyze EV protein molecular function, biological
process and molecular pathways167. Within the set of proteins identified in EVs, the top
predicted biological processes included mRNA processing, phosphorylation, response to
DNA damage stimulus and DNA dependent regulation of transcription. (Figure 5B).
FUNRICH software was used to analyze the 82 identified proteins through the UniProt
database to identify associated genes and molecular functions. The top percentile
molecular functions include gene regulation and phosphorylation. The functional groups
associated with EV proteins by percentage included nucleotide binding (20.5%), ATP
binding (17.9%), transferase activity (19.2%), DNA binding (17.9%), metal ion binding
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(17.9%), protein binding (26.9%), kinase activity (12.8%) and RNA binding (14.1%)
(Figure 5C). Next EV proteins, both unique to EVs and those shared with cells, were
correlated to top predicted functional categories and included mRNA Processing/RNA
splicing 65 (85.5%), protein transport/intracellular protein transport 52 (61.9%) or vesicle
mediated transport 34 (39.1%) and intracellular protein transport/vesicle mediated
transport 31 (47.0%) (Figure 5D). Supplemental Figure S4 shows proteins exclusively
present in EVs.

3.6. Discussion
In this work, analysis of adult mouse retinal EV release, transfer and cargo are described.
EVs released from adult retina appear heterogeneous in size and morphology, with
diameters comparable to EVs studied in other neural cell types

100,168.

The broad range

of EV diameters within our samples (10nm-900nm) may indicate release of both
microvesicles and exosomes or the release of EVs from different cell populations within
the retina with unique molecular cargo of different sizes 169,170.

The transfer of EVs containing RNA in this study suggests a novel mechanism of cell-tocell signaling within adult retinal tissue. In an earlier study, retinal pigment epithelium
(RPE) EVs, in a mouse retinal degeneration model, contained the autophagy conjugate
Atg12-Atg5 137. RPE EVs were also shown to contain  crystalline which mediates antiinflammatory processes in the neural retina

171,172.

In the CNS and PNS neurons,

microglia, astrocytes, and oligodendrocytes have been shown to release EVs with RNA
and protein cargo.173-175 CNS cell EV cargo has been shown to modulate synaptic
plasticity and regulate inflammation during neurodegeneration 173,176 In addition, CNS EVs
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have been shown to facilitate the pathogenesis of Alzheimer’s, Parkinson’s and multiple
sclerosis.177,178. EV cargo transfer in adult neural retina may be involved in healthy
physiology and pathogenesis as in the RPE and other regions of the CNS.

Of the 82 proteins detected exclusively in retinal EVs, some proteins of interest
associated with neuronal function include Cdhr1, Casz1, Sdcbp and Rdh5. Cdhr1 is an
adhesion protein involved in the binding between the outer and inner segments of the
retina. Cdhr1 is critical for retinal structure integrity and photoreceptor survival. 179,180
Casz1 is a zinc finger transcription factor that regulates neural differentiation and eye
development.

181

In the mouse retina Casz1 has been shown to be expressed in post-

mitotic cones and amacrine cells and involved in maintenance of several populations of
cells.182 Sdcbp is a multifunctional protein shown to have various roles involved in
membrane trafficking, synaptic development and cell adhesion.183 In the retina, Sdcbp
binds directly to Lrit1 which regulates cone synaptic transduction and is critical for visual
function within mice. 184 Another role of Sdcbp is neuroprotection of retinal ganglion cells,
following secretion from Müller glia. Rdh5 is a crucial protein in the phototransduction
cycle by regulating the 11-cis retinaldehyde pathway.

185

To begin to characterize the cellular origins of adult retinal EVs, we analyzed for gene
products with established expression in photoreceptors, bipolar, amacrine or ganglion
cells. Rod photoreceptors exhibit cell specific expression of rhodopsin which was
identified in isolated EVs186. Also, transcripts for the neuronal-specific nuclear
protein (Neun), a marker for a percentage of amacrine and ganglion cells was present in
both retina and EVs165. The presence of cell-specific or cell-associated molecular cargo
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in adult EVs may indicate that a percentage of the EV populations were released from
photoreceptors, horizontal or ganglion cells.

In conclusion, this study provides the first analysis of adult mouse neural retina EV release
rate, and encapsulation of RNA and protein. The data shows that retinal cell-to-cell
transfer of EVs and RNA cargo occurs leading to cytoplasmic and perinuclear localization
of up-taken EVs. Proteomic analysis demonstrates that certain proteins contained within
EVs are cell specific and preserve retinal function. As additional data is generated, retinal
EVs may be shown to be involved in diverse functions including synaptogenesis,
neuroprotection, physiology and disease.

The cargo of stem and neural progenitor EVs has been correlated to early developmental
signaling and neuronal differentiation

111,112,156,187.

EVs secreted from human embryonic

stem cells (hESCs) contain factors that induce pluripotentcy, namely oct-4, nanog, and
gata-4 113,188 113. Similarly, induced pluripotent stem cell (iPSC) EVs encapsulate mRNA
of the transcription factors Oct-3/4, Nanog, Klf4, and C-Myc

187.

Our recent analysis of

retinal progenitor cell (RPC) EVs revealed cargo associated with multipotency including
Pax6, Hes1, Ki67, Nestin. Using a Cre-loxP system functional transfer of EV molecular
cargo was demonstrated between RPC populations 156.

Adult CNS EV function includes maintenance of neurogenic niches, neuroprotection and
modulation of synaptic plasticity

114-116,189.

Neuroprotective astrocyte EV cargo includes

Hsp/Hsc70, synapsin and FGF-2.148,190. Oligodendrocyte EVs facilitate neurite outgrowth,
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reduce inflammation
metabolic activity

114-116

114,191.

transfer mRNA to axons supporting axon structure and

Depolarization enhanced release of EV cargo predicted to

facilitate adult synaptic plasticity include Ca

2+

/calmodulin-dependent protein kinase,

neuronal adhesion molecule L1, and AMPA receptor subunits 189,192.

In this new work, we provide the first analysis of adult retina EV release rate, ultrastructure
and molecular cargo. A steady EV release rate was analyzed from complete neural retina
and revealed classical EV morphology containing markers for exosomes and
microvesicles. The expression of adult retinal cell genes is reflected in EV cargo mRNA.
The EV lipid-encapsulation and transfer of mRNA between adult retinal cells was
visualized over a physiologically relevant time course. The proteomic profile of retina and
EVs showed 857 shared protein species and 82 detected only in EVs. The significance
of EV cargo selection by releasing cells and the role of EV transfer in the retinal
microenvironment will require ongoing studies. The data suggests that adult retina EV
release and molecular cargo may be valuable markers of normal retinal physiology,
pathogenesis and response to therapeutic interventions.

3.7. Methods
3.7.1. Retina Isolation and Culture
All experiments were approved by and performed in compliance with the City University
of New York, Lehman College Animal Care and Use Committee (IACUC). C57BL/6J mice
age 3–6 months were euthanized, whole eyes collected (n=16) and the anterior segments
cut away at the ora serrata. The vitreous and RPE were removed from neural retina.
Neural retinas were cultured in 6-well plates in 5mL of Dulbecco's Modified Eagle Medium
(DMEM) media plus 10% Exosome Free Fetal Bovine Serum (FBS), 1% Penicillin
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Streptomycin and 0.2% Nystatin and cultured at 37ºC. Retina conditioned media and
retina were collected after five days for analysis.

3.7.2. Retina Viability Assay
Retina were isolated and cultured as above in 6-well plates with 5ml of Dulbecco's
Modified Eagle Medium (DMEM) media plus 10% Exosome Free Fetal Bovine Serum
(FBS), 1% Penicillin Streptomycin and 0.2% Nystatin and cultured at 37ºC, 5% CO 2.
100uL of conditioned media was collected from 3 wells every 24hrs for up to five days
and analyzed for viability using a 96-well plate reader. 10ul of WST (Sigma) reagent was
mixed with isolated experimental media and placed in 37ºC, 5% CO2 incubator for 4
hours. WST absorbance was read at 480nm as an indicator of cell number and viability.

3.7.3. Nanosight Analysis
EV diameter and concentration were assessed using the NanoSight NS500 system.
Retina conditioned media was collected at 5 days of culture and transferred to centrifuge
tubes. Media was centrifuged at 300 × g for 10 min at 4 °C to pellet cell debris.
Supernatant was transferred to an ultracentrifuge tube (Beckman Coulter), spun at
10,000 × g for 20 min using 60Ti rotor (Beckman Coulter ultracentrifuge) at 4 °C. Control
non-conditioned media was processed using identical steps. Supernatant was diluted at
1:20 in PBS and 1ml was used for NanoSight analysis. Nanoparticle Tracking Analysis
(NTA) software 2.3 was used to track trajectories and diameters of nanoparticles. Results
are displayed as frequency sized distribution graphs describing the number of particles
per milliliter. The concentration of released EVs was calculated to determine the average
number of EVs with standard deviation in conditioned media compared to control and
analyzed using a Student’s t-test.
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3.7.4. Extracellular vesicle isolation
Conditioned media was collected from 6-well plates and extracted with Exoquick TC
(System Biosciences). Briefly, 10mL of conditional media was collected and centrifuged
at a speed of 3000g for 15 minutes to remove cell debris. The supernatant was collected,
mixed with 2mL of Exoquick TC solution and inverted 5 times. The solution was then
placed at 4 °C for 12 hours. Following Incubation at 4 °C, media was centrifuged at 1500g
for 30 minutes. Post spin supernatant was aspirated and an EV pellet collected from the
tube wall. The pellet was then analyzed for protein and RNA content.

3.7.5. Retina and extracellular vesicle RNA isolation
Total RNA was extracted and purified from EV pellets and retinal tissue using the RNeasy
Plus Mini Kit (Qiagen) according to the manufacturer's protocol. Briefly, the EV pellet or
retinal tissue was mixed with 350μl buffer RLT Plus and 10μl β-Mercaptoethanol and
vortexed for 15 seconds. Lysate was transferred to a gDNA eliminator spin column,
placed in a 2ml collection tube and centrifuged for 30 s at 8100 x g. The flow-through was
mixed with 350μl of 70% ethanol and transferred to an RNeasy spin column in a 2ml
collection tube, centrifuged for 15 s at 8100 x g and flow through-discarded. Next, 700μl
of buffer RW1 was added to the RNeasy mini spin column, centrifuged for 15 s at 8100 x
g and flow-through discarded. Next 500μl of buffer RPE was added to the RNeasy spin
column and centrifuge for 15 s at 8100 x g and flow-through discarded. Next 500μl buffer
RPE was added to the RNeasy spin column, centrifuged for 2 min at 8100 x g. Lastly, the
RNeasy spin column was placed in a new 1.5 ml collection tube, 50μl RNase-free water
was added and centrifuged for 1 min at 8000 x g to elute the RNA. RNA was screened
for purity and concentration using a Nanodrop-1000 spectrophotometer.
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3.7.6. Western blot analysis
Total protein was extracted from EVs and retina tissue using Pierce IP lysis Buffer (50μl)
(Thermo Scientific Fisher) and 100X protease inhibitor. Protein lysate was centrifuged for
15 min at 12,000 RPM at 4°C, supernatant collected, mixed with 6X sample buffer and
heated at 75°C for 15 minutes. Protein samples were loaded on 4-12% gel cassettes and
loaded into a Mini Gel Tank (Invitrogen) filled with 1X running buffer and run at 200V for
45 mins. The gels were transferred to nitrocellulose membrane and incubated in Odyssey
blocking solution for 45 minutes followed by incubation with primary antibody overnight at
4°C. The membrane was then rinsed with 1X TBS-T three times for 5 min each followed
by incubation with secondary antibody for 45 minutes at 4°C. The membrane was washed
three times with 1X TBS-T for 5 minutes and then protein bands analyzed using the
Odyssey Clx imaging system.

3.7.7. Quantitative real-time PCR
Total RNA (1 µg) was reverse-transcribed to produce complementary DNA (cDNA) using
the New England Biolabs Protoscript AMV First Strand cDNA Synthesis Kit according to
the manufacturer’s protocol. Briefly, isolated RNA was mixed with d (T) 23 primer and
denatured for 5 min at 70°C. AMV reaction mix buffer, enzyme mix of reverse
transcriptase and murine RNase inhibitor was added to the sample and incubated at 42°C
for 1 hour. The AMV enzyme was inactivated via incubation at 80°C for 5 min. The cDNA
product was diluted with 30μl nuclease-free water and analyzed using SYBR Green ER
qPCR Supermix. According to the iCycler protocol 12.5µL of SYBR GreenER qPCR
Supermix, 0.5 µL of forward and reverse primers and 1µL of cDNA template were
combined and DEPC water added to bring the volume to 25µL. Samples were prepared
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in triplicates and mixed in a PCR plate followed by amplification and melting curve
analysis using a Bio-Rad iCycler.

Table 1. Primers and product sizes for qRT-PCR.
Gene

Primer sequence (5′–3′)

Klf14

F: TCT TGG ATT TGG GGT GAG AG 276

(bp)

R: GGG ATC ATA GGG GAC CTC AT
Smoc
Igsf8

F:
R:
F:
R:

GGG ACT TCC ACA CGC TAT GT 169
CCT GAA CCA TGT CTG TGG TG
GCA CCG CTG TCT CTA TCT CC 293
GTT GCC CAG GTA CTG CGT AT

Gprc5b F: AGT TCA AAC GGT GGA AGG TG 247
R: TAG TTG GGT GGG TTC TCC TG
β-actin F: TTC CAG CCT TCC TTC TTG
R: GGA GCC AGA GCA GTA ATC
GAPDH F: AAC TTT GGC ATT GTG GAA GG 223
R: ACA CAT TGG GGG TAG GAA CA

3.7.8. Transmission electron microscopy (TEM)
EVs isolated from conditioned media were fixed in 2.5% glutaraldehyde with 4%
paraformaldehyde (EM grade) for 2.5 hours and washed in PBS for 24 hours. EVs were
post-fixed in osmium tetroxide for 30 min, washed with distilled water and subsequently
dehydrated using increasing ethanol concentrations (70%, 85%, 95% and 100%), each
for 10 minutes. Sample dehydration was followed by immersion in propylene for 20
minutes, twice. Samples were infiltrated with a 1:1 mixture of propylene oxide and Spurr’s
Resin for 1 hour, left in 100% Spurr’s Resin overnight. Samples were then embedded in
beem capsules using fresh Spurr’s Resin at 70°C for polymerization. Excess resin was
trimmed and 90 nm sections of samples were made using a Leica Ultramicrotome.
Sections were placed on 200 mesh copper grids, stained with saturated uranyl acetate in
50% ethanol for 6 minutes, rinsed in water and stained for 90 seconds in lead citrate.
Grids were then rinsed in water, dried on filter paper and viewed under a Fei Tecnai
transmission electron microscope operated at 80 kV. Images were obtained using an
AMT camera with AMT digital software.
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3.7.9. Immunoelectron microscopy
5μl of resuspended 2% paraformaldehyde fixed EVs were put on glow discharged
formvar-carbon coated nickel grids. After washing with PBS, the grids were incubated
with 50mM glycine/PBS for 3 min. The grids were blocked for 10 min with 1% coldwater
fish skin gelatin (Sigma-Aldrich) for the surface immunolabeling (Tsg101, CD63 Abcam).
Primary antibodies were suspended in blocking solution and applied for 2 hours at room
temperature. Controls were prepared in the absence of primary antibodies. After washing
with PBS, Nanogold-labeled Fab’ anti-rabbit or anti-mouse (Nanoprobes, NY), or 5nm,
10nm gold conjugated goat anti-mouse antibodies (Ted Pella Inc. Redding, CA) were
applied in the correlated antibody incubation buffer for 1 hour. The grids were then
washed with PBS and fixed in 1% glutaraldehyde for 5 min. After thoroughly washing with
distilled water, the grids were either placed directly into methylcellulose for 5 nm or 10 nm
gold embedding or allowed to continue with silver enhancement of nanogold. For the
silver enhancement, the grids were washed with 0.02 M sodium citrate (pH 7.0), and
performed silver enhancement in the dark using HQ Silver enhancement kit (Nanoprobes,
NY) at room temperature for 8 min. After washing with distilled water, the grids were
contrasted and embedded in a mixture of 3% uranyl acetate and 2% methylcellulose in a
ratio of 1–9. Stained grids were examined under Philips CM-12 electron microscope and
photographed with a Gatan (1k×1k) digital camera. All antibodies were purchased from
Abcam, USA and diluted Anti-Tsg101 (1:200), CD63 (1:200) according to manufacturer’s
instruction, followed by imaging as described above.
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3.7.10. Retinal RNA labeling and EV RNA cargo Transfer Analysis
Using the culture and isolation methods described above, the RNA specific dye SytoRNA
Select (Invitrogen) was used on whole mouse retinas with minor modifications to
manufacturer’s protocol. Retinas were placed in a 2.5uM solution of dye and incubated
at 37°C, 5 CO2 for one hour and then rinsed three times with fresh media. SytoRNA
labeled retina were then incubated in the TRITC fluorescent lipophilic dye PKH26 (Sigma)
according to manufacturer’s instructions. Whole retina was placed in 500uL diluent and
transferred to a 4 ×10-6 M dye solution, and incubated at room temperature for 15 minutes
on an orbital shaker. 1 mL of HI-FBS was used to quench labeling. SytoRNA and PKH26
labelled retina was washed in fresh culture medium 3X and transferred to 6 well plates
containing fresh media.

3.7.11. Transwell Extracellular Vesicle Diffusion Culture
Retinas were collected as described above, lightly dissociated by trituration, and cultured
in 12 well glass bottom plates (MatTek corporation). Whole retina stained with SytoRNA
Select (Invitrogen) and PKH26 (Sigma), as described above, were cultured in Transwell
inserts with 0.4μm pore PET membranes above non-labeled dissociated retina and cocultured for five days. Double SytoRNA (green) RNA and PKH26 (red) lipid labelled EVs
released by adult retina diffused through the transwell membrane pores and were imaged
contacting cells on glass-bottom wells.

3.7.12. Super resolution Imaging of retinal cells containing Transferred EVs
Following transwell diffusion of EVs double labeled with SytoRNA (RNA) and PKH26
(lipid) (above)target adult retinal neurons from glass bottom wells containing adherent or
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internalized EVs were fixed with 4% PFA and mounted with DAPI Prolong Gold mounting
media for imaging. Multichannel structured illumination microscopy (SIM) images were
acquired using a Nikon Structured Illumination N-SIM system on an inverted Nikon
ECLIPSE Ti-E equipped with a 100× 1.49 NA objective. Multicolor fluorescence was
generated using diode lasers (488, 561 and 647 nm). Z stack images were acquired using
the electron-multiplying CCD cameras (Andor iXon3 DU897) 512 × 512 pixel frame size.
Three reconstruction parameters (Illumination Modulation Contrast, High Resolution
Noise Suppression and Out of Focus Blur Suppression) were extensively tested to
generate consistent images across experiments without abnormal features or artifacts
and producing the best Fourier transforms. The acquired images were then processed
using Nikon Elements software. 3D reconstruction was generated using Imaris software
(Bitplane).

3.7.13. Mass spectrometry
Whole cell lysate and exosome-enriched samples from mouse retina were denatured in
8M urea, reduced with 10mM DTT, and alkylated with 50mM iodoacetamide. This was
followed by proteolytic digestion with endoproteinase LysC (Wako Chemicals) overnight,
and with trypsin (Promega) for 6h at room temperature. The digestion was quenched with
2% formic acid and resulting peptide mixtures were desalted using in house made C18
Empore (3M) StAGE tips.

193.

Samples were dried and resolubilized in 2% acetonitrile

and 2%formic acid. Approximately 1μg of each sample was injected for analysis by
reversed phasenano-LC-MS/MS (Ultimate 3000 coupled to a QExactive Plus, Thermo
Scientific). After loading on a C18 trap column (PepMap, 5μm particles, 100μm x 2cm,
Thermo Scientific) peptides were separated using a 12 cm x 75μm C18 column (3μm
particles, Nikkyo Technos Co., Ltd. Japan) at a flow rate of 200 nL/min, with a gradient
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increasing from 5% BufferB (0.1% formic acid in acetonitrile) / 95% Buffer A (0.1% formic
acid) to 40% Buffer B / 60%Buffer A, over 140 minutes. All LC-MS/MS experiments were
performed in data dependent mode with lock mass of m/z 445.12003 194. Precursor mass
spectra were recorded in a 300-1400m/z range at 70,000 resolutions, and fragment ions
at 17,500 resolutions (lowest mass: m/z 100). Up to twenty precursors per cycle were
selected for fragmentation and dynamic exclusion was set to 60s. Normalized collision
energy was set to 27.

3.7.14. Protein profiling analysis
Mass spectrometry data were searched against a Uniprot mouse database (July 2014)
using MaxQuant (version 1.5.0.30

194).

Oxidation of methionine and N-terminal protein

acetylation were allowed as variable modifications, while all cysteines were treated as
being carbamidomethylated. Precursor mass tolerance was set at 4.5 ppm while a 20
ppm tolerance was allowed for fragment ions. Two missed cleavages were allowed for
specific tryptic search. The “match between runs” option was enabled. False discovery
rates at the protein and peptide level were set to 1%. Protein abundances were
represented by LFQ (Label Free Quantitation) and iBAQ (intensity-Based Absolute
Quantitation)

195.

iBAQ values were log2(x) transformed and further used to create box

plots to depict the distribution and changes in protein expression between two samples.
Protein abundances were represented by LFQ (Label Free Quantitation) and iBAQ
(intensity-Based Absolute Quantitation) 195.
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4. Human retina EVs as a marker for Diabetic Retinopathy
We next characterized EVs released from adult non-diabetic and diabetic retinopathy
(DR) retina in vitro.

4.1. Characterization of EVs from diabetic and non-diabetic human retina.
To characterize EVs released from human retinal tissue we performed Nanosight analysis
of media conditioned from cultured diabetic or non-diabetic human retina. Retinas were
cultured for five days and EV-enriched media analyzed using Nanosight. Readings were
normalized to control media. Nanosight Tracking Analysis (NTA) data quantified human
retina released EV concentrations and diameters (Figure 6). The diameter and
concentration distribution plot for both samples are shown in Figure 6A, B for non-diabetic
and diabetic retina, respectively.

The red lines show deviation within the triplicate

samples used in the analysis. There was a significant difference in the diameters of EVs
released between non-diabetic (193.8nm ± 6.525) and diabetic retina (157.5nm ± 6.176)
in vitro, as shown in Figure 6C.
Figure 6. Non-diabetic retina releases
larger and more concentrated EVs. A)
Density plots of released EVs from nondiabetic and B) diabetic retina showing
concentration vs size distribution. C) Average
size of EVs from Non-Diabetic (193.8 ± 6.525,
n=3) vs Diabetic (157.5 ± 6.176, n=3) Twotailed T test with a Welch’s correction showed
significance of p=0.001. D. Average
concentration of particles released of EVs
from
Non-Diabetic
(1627777778
±
169932812, n=3) vs Diabetic (868555556 ±
156087414, n=3) Two tailed T test showed
significance of p=0.0046. All concentration
values were normalized with measurements
from culture medium used for analysis.

The average diameter of non-diabetic retina EVs (193.8 ± 6.525) was significantly larger
than diabetic EVs (157.5 ± 6.176), p=0.001. The average concentration of EVs released
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between samples was compared (Figure 6D) and revealed that non-diabetic EV media
concentrations (1.63E+09 ± 1.70E+08) were significantly higher than diabetic
concentrations (8.69E+08 ± 1.56E+08), p=0.004. The result reveals an approximate 1.8
fold in concentration and a 1.2 fold in size between EVs released from non-diabeticand
diabetic retina, respectively.

4.2. Ultrastructure of EVs released from diabetic and non-diabetic human retina.
To confirm EV marker localization, we used immunogold TEM analysis to detect the
Figure 7. Human retinal EV ultrastructure and
marker localization. TEM imaging of EVs isolated
from conditioned media from left to right Negative stain
control, CD63 and TSG 101 antibody. Images show
positive stains for both CD63 and TSG 101.

presence of appropriate EV tetraspan proteins. The canonical markers TSG101 and
CD63 were used to confirm EV and were co-localized to lipid membranes (Figure 7).

4.3. Viability of human retina in vitro.
We
Figure 8. WST viability analysis of
human retina over 5 days. Culture
medium was collected from wells where
retinal tissue was grown over a 5 days
period and analyzed with WST viability
assay. Bar graph shows absorbance
reading between time points.

performed

viability

assays on retinal explants
to confirm that while in
culture,

during

EV

collection, no significant decrease in viability was observed. Using a
WST-1 colorimetric assay no significant differences in viability occurred during culture
over the duration of EV collection.
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4.4. Super resolution Imaging of isolated retinal cells internalizing EVs released
from retinal tissue.
To determine if EVs could be transferred between retinal cells, a transwell experiment
was performed. Whole retina
was

labeled

fluorescent
(PKH26)

with

dye

and

a

red

lipid

dye

simultaneously

with a green fluorescent RNA
specific dye (Syto Green). The
labeled retina was then placed
into a transwell filter with 0.4µ
diameter pores above

Figure 9. Lipid membrane and RNA labeled EVs released
from adult human retina are up-taken by unlabeled retinal
cells. Super-resolution microscopy was used to visualize RNA
(SytoRNA/green) and lipid membrane (PKH26/red) labeled EVs
released from adult retina and taken up by control non-labeled
adult retinal cells in a transfer experiment. Adult retinal cell with
internalized EVs imaged for transferred A) lipid
membrane (TRITC/red) B) total RNA (FITC/green), C) nuclei
labeled with (DAPI) and D) Overlay reveals co-localization of
transferred EVs with visible RNA and lipid membrane within the
proximity of the perinuclear envelope of receiving retinal cells.

labeled

dissociated

neurons.

EVs

from

nonretinal

labeled

retina were imaged with red lipid
membrane

and

green

RNA

cargo landing on and being up
taken by isolated retinal cells
over 4 days (Figure 9). The
images revealed that labeled

EVs released from adult retina are internalized of by target cells and localize to the
cytoplasmic space in regions potentially containing endoplasmic reticulum, Golgi
apparatus and perinuclear envelope.

41

4.5. Characterization of diabetic and non-diabetic human retina and released EV
cargo.
Mass
was

spectroscopy
performed

characterize

protein

signatures
retinal

to

in

both

tissue

and

encapsulated

in

released EVs. Protein
samples were isolated
Figure 10. Distinct proteomic cargo between human retina and
released EVs. Proteomic data was analyzed to determine shared and
unique signatures across samples. A) Number of protein species present
in non-diabetic and diabetic retinal tissue, B) non-diabetic retina EVs and
diabetic retina EVs, C) Non-diabetic retina and non-diabetic retina EVs. D)
diabetic retina and diabetic retina EVs. To correlate protein species
identified in retinal EV samples the Vesiclepedia database was used. E)
Non-diabetic retina EV and diabetic retina EV protein overlayed with the
Vesiclepedia database showed 1501 shared species. N= 2 for all four
sample groups

from

non-diabetic

retina, diabetic retina
and

corresponding

EVs. The number of

proteins present and distributed within samples is summarized in Figure 10. Analysis of
non-diabetic

and

diabetic

retina

samples

revealed

1890 shared proteins,
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belonging

exclusively to nonFigure 11. Identified EV proteins are enriched in retina with predicted
roles in retinal function. A) Functional enrichment analysis of 23 shared
diabetic and non-diabetic retina EVs have significant site of expression in
retina, rods and cones compared to other organ tissues. B) STRING pathway
analysis reveals functions of identified proteins associated with retinal
physiology and visual cycle.

diabetic

and

306

found exclusively in
the

diabetic

retina

(Figure 10A).
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We then analyzed non-diabetic EVs, diabetic EVs and identified 1163 shared proteins
(Figure 10B), 530 unique to diabetic and 232 unique to non-diabetic EVs. These results
show a higher number of protein species present in diabetic EVs compared to nondiabetic EVs. We then analyzed protein numbers between non-diabetic retina nondiabetic retina and EVs and found 1176 shared proteins, 1167 detected only in nondiabetic tissue and 219 were exclusively in the EVs (Figure 10C). Similarly, in diabetic
retina and EVs and found 1322 shared proteins, 874 detected solely in tissue and 371
distinct to EVs (Figure 10D) (For list of proteins see Supplementary Figure 1a-d). The
results show that while a high percentage of proteins are shared between retina and their
released EVs, a percentage of species are detected only in EVs. To confirm that the
protein signatures we identified were validated in other EVs studies, we cross-referenced
EV proteins detected in retinal EVs with the human protein database from Vesiclepedia
(Figure 10E). There were 1501 proteins detected in our EV samples that correlated
proteins identified in publications supporting the Vesiclepedia database. The analysis of
neural retinal tissue has not been described in the EV literature, suggesting that we may
be detecting novel database, with 23 proteins shared between non-diabetic and diabetic
EVs, 16 in diabetic EVs alone and 19 in non-diabetic EVs alone. To begin to elucidate
the significance of association of retina EV proteins detected we used bioinformatics to
analyze the 23 proteins shared between non-diabetic and diabetic EVs and determined
that significant enrichment in retina, rods and cones. (Figure 11A).
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Name
C22orf28

RCVRN.
SF3B14
GNGT1

MSI1
RPE65.
BBS7
MPP2
HNRPDL

RHO
KIAA1967

UNC119

PDC

MGAT3
KIAA1279
C6orf211

IMPG1
ERI3
RS1
DAK

MGARP
PDE6B.
CORO2B

Function of protein (STRING)
Chromosome 22 open reading frame 28; Catalytic subunit of the tRNA-splicing ligase complex that
acts by directly joining spliced tRNA halves to mature-sized tRNAs by incorporating the precursorderived splice junction phosphate into the mature tRNA as a canonical 3’,5’- phosphodiester
Recoverin; Seems to be implicated in the pathway from retinal rod guanylate cyclase to rhodopsin
Pre-mRNA branch site protein p14 ; Necessary for the splicing of pre-mRNA. Directly contacts the
pre-mRNA branch site adenosine for the first catalytic step of splicing.
Guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1; Guanine
nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various
transmembrane signaling systems.
Musashi homolog 1 (Drosophila); RNA binding protein that regulates the expression of target
mRNAs at the translation level. Regulates expression of the NOTCH1 antagonist NUMB.
Retinal pigment epithelium-specific protein 65kDa; Plays important roles in the production of 11-cis
retinal and in visual pigment regeneration
Bardet-Biedl syndrome 7; The BBSome complex is thought to function as a coat complex required
for sorting of specific membrane proteins to the primary cilia.
Membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) (552 aa)
Heterogeneous nuclear ribonucleoprotein D-like; Acts as a transcriptional regulator. Promotes
transcription repression. Promotes transcription activation in differentiated myotubes (By similarity).
Binds to double- and single-stranded DNA sequences.
Rhodopsin; Photoreceptor required for image-forming vision at low light intensity.
KIAA1967; Core component of the DBIRD complex, a multiprotein complex that acts at the interface
between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation
with the regulation of alternative splicing- the DBIRD complex affects local transcript elongation rates
and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions.
Unc-119 homolog (C. elegans); Involved in synaptic functions in photoreceptor cells, the signal
transduction in immune cells as a Src family kinase activator, endosome recycling, the uptake of
bacteria and endocytosis, protein trafficking in sensory neurons and as lipid- binding chaperone with
specificity for a diverse subset of myristoylated proteins.
Phosducin; May participate in the regulation of visual phototransduction or in the integration of
photoreceptor metabolism. Inhibits the transcriptional activation activity of the cone-rod homeobox
CRX (246 aa)
Mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase; It is involved in the
regulation of the biosynthesis and biological function of glycoprotein oligosaccharides
KIAA1279; Required for organization of axonal microtubules, and axonal outgrowth and
maintenance during peripheral and central nervous system development)
Chromosome 6 open reading frame 211; O-methyltransferase that methylates glutamate residues
of target proteins to form gamma-glutamyl methyl ester residues. Methylates PCNA, suggesting it is
involved in the DNA damage response
Interphotoreceptor matrix proteoglycan 1; May interact with hyaluronan which may serve to form a
basic macromolecular scaffold comprising the insoluble interphotoreceptor matrix
ERI1 exoribonuclease family member 3
Retinoschisin 1; May be active in cell adhesion processes during retinal development
Dihydroxyacetone kinase 2 homolog (S. cerevisiae); Catalyzes both the phosphorylation of
dihydroxyacetone and of glyceraldehyde, and the splitting of ribonucleoside diphosphate-X
compounds among which FAD is the best substrate.
Mitochondria-localized glutamic acid-rich protein; Plays a role in the trafficking of mitochondria along
microtubules
Phosphodiesterase 6B, cGMP-specific, rod, beta; This protein participates in processes of
transmission and amplification of the visual signal
Coronin, actin binding protein, 2B; May play a role in the reorganization of neuronal actin structure

Table 2. STRING functional analysis of novel proteins contained in non-diabetic and diabetic retina
EVs. Identified EV proteins have predicted functions associated with visual processing (RCVRN, RHO,
RPE65, PDE6B), cell structure (RS1, CORO2B) interphotoreceptor matrix structure (IMPG1), cone-rod
transcription (PDC), post-transcriptional modification (C22orf28, SF3B14), and cell signaling (GNGT1,
MSI1, BBS7, MPP20, UNC119).
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retinal EV signatures. We detected a total of 58 proteins not listed in the
bioinformatics results support that proteins detected in EVs from both diabetic and nondiabetic retinas are strongly
predicted to be expressed
in retinal tissue. STRING
analysis of the 23 novel
proteins identified roles in
the visual cycle process
depicted with protein to
protein
Figure 12. Predicted biologic processes correlated to diabetic
retina EV proteins. Functional enrichment analysis of diabetic retina
EV proteins determined significant correlation to biological processes
associated with diabetic retinopathy including immune cell migration,
carbohydrate mediated signaling, protein folding and metabolism.
Red = percentage of gene, green = p=0.05 reference and blue = pvalue FunRich was used to perform hypergeometric test with
Benjamini-Hochberg method correction.

Figure

interactions
11B.

in
The

predicted roles for retinal
EV

proteins

are

described in Table 2.

Beyond roles in visual processing (RCVRN, RHO, RPE65, PDE6B), protein functions
identified include roles in cell structure (RS1, CORO2B) interphotoreceptor matrix
structure (IMPG1), cone-rod transcription (PDC), post-transcriptional modification
(C22orf28, SF3B14), and signaling pathways (GNGT1, MSI1, BBS7, MPP20, UNC119).

The 16 novel proteins identified in diabetic retina EVs were analyzed to determine
predicted functional roles in diabetic pathogenesis (Figure 12). Functional enrichment
analysis for biological processes predicted significance in metabolism, protein folding and
carbohydrate mediated signaling, which correlate well with diabetic insulin signaling and
diabetic retinopathy progression. We also found significant fold changes in proteins
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related to immune cell migration which is a key pathway in the pathogenesis in DR. These
results suggested a role for DR EVs in pathogenesis.

Functional enrichment analysis was performed using a background dataset to model
biologic process fold enrichment using a hypergeometric test, BH method and corrected
p values (Figure 13). We analyzed protein associated functional differences between nondiabetic retina and diabetic retina. Compared to non-diabetic retina, diabetic retina
showed significant fold increases in regulation of cell shape, mitochondrial transport, lipid
and xenobiotic metabolism (Figure 13A). Significant fold decreases in diabetic retina
included synapse organization, biogenesis, extracellular structure organization and DNA
repair. Diabetic retina biologic process fold change values correlate to processes
increased in diabetic retinopathy including mitochondrial reactivity, changes in endothelial
shape, reduction in extracellular integrity and synapse organization. Protein associated
functional differences were then analyzed between non-diabetic retina EVs and diabetic
retina EVs and significant fold increases for diabetic retina EVs were seen for
carbohydrate mediated signaling, wound healing, cell proliferation and immune response
(Figure 13 B). Diabetic retina EV biologic processes with significant fold decreases were
DNA repair, regulation of cell cycle, cytoskeletal anchoring and carbohydrate metabolism
(Figure 13B). These results suggest that biologic processes correlated to diabetic retina
and diabetic retina EV proteins are associated with diabetic retinopathy processes
including angiogenesis, endothelial cell dysfunction and immune response, decreased
structural integrity and insulin signaling.
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Figure 13. Functional enrichment analysis modeling of biologic process fold enrichment
correlated to diabetic retina and EVs proteins. A) Analysis of biologic process fold change values
between diabetic retina and non-diabetic retina reveal increased regulation of cell shape, mitochondrial
transport, lipid and xenobiotic metabolism in diabetic retina. B) Analysis of fold changes between diabetic
retina EVs and non-diabetic retina EVs shows significant fold change increases for diabetic retina EVs
including carbohydrate mediated signaling, wound healing, cell proliferation, immune response and
decreases for DNA repair, regulation of cell cycle, cytoskeletal anchoring and carbohydrate metabolism.
FunRich was used to perform hypergeometric test with Benjamini-Hochberg method correction

The

1693

EV

proteins

shared between diabetic
retina
Figure 14. Diabetic retina and EV proteins identified with a 4fold change in area abundance. A) Venn diagram showing
proteins upregulated above a 4-fold threshold in diabetic retina
and EV samples. B) Venn diagram showing proteins
downregulated above a 4-fold area abundance in diabetic retina
and EV samples.

and

EVs

were

analyzed for area abundance
as a predictor of association
to pathogenic processes in

diabetic retinopathy. Proteins were selected with fold up or down fold changes of 4 or
more using Proteome Discoverer software. Analysis revealed a total of 37 proteins with
a 4-fold or greater increased abundance in diabetic retinal tissue compared to nondiabetic retinal tissue (Figure 14A). Additionally, 100 proteins in diabetic retina EVs
showed a 4-fold or greater increased abundance compared to non-diabetic retina EVs
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Figure 15. Diabetic retina
and released EV protein area
abundance levels associate
with pathogenic processes
of diabetic retinopathy. A)
Analysis of molecular functions
associated with increased area
abundance
(upregulated)
proteins found in diabetic
retina samples. B) Functional
enrichment
analysis
of
molecular functions associated
decreased area abundance
(downregulated)
proteins
found in diabetic retina
samples.

(Figure

14A).

Decreased

area

of

abundance (4-fold or
greater) was seen in 51
EV

exclusive,

675

retina, and 27 shared
diabetic

retina-EV

proteins. (For list of
proteins and functions see Supplementary Figure
1e-f and Supplementary Table 1a-c). We then correlated changes in area abundances
across retina and EV samples and determined associations with DR pathogenic
processes.

Several pathways related to
DR

were

associated

proteins exhibiting 4-fold or
greater changes in area
abundance
Figure 16. Biologic processes correlated to upregulated diabetic
retina proteins. Bar graph showing biological process of upregulated
proteins found in diabetic retina tissue.

in

diabetic

retina and EVs (Figure
15). Positive DR pathways

associated with 4-fold increased proteins include VEGF signaling, insulin pathways, HIF
alpha-1, Ar6 downstream pathways and amb2 signaling (Figure 15A). DR pathways
associated with 4-fold decreased proteins include visual signal transduction, retrograde
neurotrophin signaling, L1CAM interactions, mTOR-c1 mediated signaling and release of
eIF4e (Figure 15B).
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4-fold

increased proteins

from diabetic retina were
further

analyzed

Panther
database
biological

Gene
to

using
ontology

determine

processes

and

protein classes associated
Figure 17. Protein classes identified from upregulated
diabetic retina proteins. Bar graph showing protein classes of
upregulated proteins found in diabetic retina tissue.

with these populations. Of
the 37 upregulated proteins

found in diabetic retina, the Panther database matched 23 genes with 38 associated
processes (Figure 16). The most significantly correlated pathway was metabolic process
in which 10 genes were associated. Other DR associated processes included biological
adhesion, biological regulation, immune system and cellular component analysis. To
elucidate

protein

classes contributing to
DR

associated

processes,
analyzed

we
the

23

genes from above and
identified 15 unique
Figure 18. Biological processes correlated to upregulated diabetic
protein
retina EV proteins. Bar graph showing biological processes correlated
to upregulated proteins present in diabetic retina EVS

classes (Figure

17). The protein class
with the highest number of correlated genes (n=3) was oxidoreductase, which is central
in the development of reactive oxygen species in DR. Other protein classes associated
with DR included signaling molecules, transferases and calcium binding proteins. Next
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the biological processes and protein classes of upregulated proteins in diabetic retina
EVs were analyzed for their role in DR. From the 100 upregulated EV proteins, 83 were
mapped to genes correlated to 90 biological process in the Panther database (Figure 18).
Metabolism was the process most associated to proteins in diabetic retina EVs with 18
correlated genes. Other processes included cellular processes, response to stimulus,
cellular component

Figure 19. Networks
correlated to proteins
found exclusively in
diabetic retina EVs play
a role DR progression.
FunRich interaction map
showing
enriched
pathways and gene count
for proteins found in
diabetic EVs and not
diabetic retina.

organization,
system

immune

process

biologic

and

regulation.

From the 83 mapped
genes, 51 protein classes were identified with oxidoreductase being the most abundant
correlated to 8 genes (Figure 21). Other protein classes included nucleic acid binding,
signaling molecule, cytoskeletal protein, enzyme modulator and hydrolases.
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Figure
20.
Networks
correlated to proteins
found exclusively in nondiabetic EVs play a role
gene regulation. FunRich
interaction map showing
enriched pathways and
gene count for proteins
found in non-diabetic EVs
and not non-diabetic retina.

The next was to determine if proteins secreted exclusively in diabetic or non-diabetic
retina EVs shared the same function. To do this we analyzed the 371 diabetic EVs and
the 219 non-diabetic EVs that were not detected in their parent retina (Figure 18). FunRich
interaction mapping software was used to visualize pathways associated with these EV
specific proteins. For proteins exclusively detected in diabetic retina EVs, correlations to
networks associated with DR pathogenesis were identified, including integrin cell surface
interactions, fibrin clots, metabolism of proteins, ceruloplasmin and eukaryotic translation
initiation (Figure 19).
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These pathways are associated with diabetic process, the development and progression
of DR. As a control, the networks associated with proteins found exclusively in nondiabetic EVs were analyzed and showed no correlation to pathology or retinal disease
(Figure 20), Non-diabetic retina EVs
showed
enrichment in networks regulating
gene expression, gene processing
and mRNA mechanisms. These
results support the hypothesis that
diabetic retina EVs contain specific
Figure 21. Protein classes identified from
upregulated diabetic retina EVS proteins. Bar graph
showing protein classes of upregulated proteins found in
diabetic retina EVs.

proteins, not detected in retina, that
play a role in DR pathogenesis.
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4.6. Next Generation Sequencing of EV cargo from diabetic and non-diabetic
human retina in vitro
Next, small RNA next-generation sequencing analysis was performed on EVs released
from non-diabetic (control) and diabetic retina in vitro. The analysis identified 301 miRNA

Figure 22. Diabetic retina EVs contain unique miRNA signatures correlated to DR pathogenesis.
A) Number of miRNA species present in EVs released from diabetic and non-diabetic retinal tissue in vitro.
B) Functional enrichment analysis of diabetic retina EV miRNAs determined significant correlation to
biological pathways associated with diabetic retinopathy including VEGF signaling, endothelins, TRAIL and
estrogen receptor signaling. C) Analysis of miRNA correlated biologic process fold changes between diabetic
retina EVs and non-diabetic retina EVs shows significant increases for diabetic retina EVs for apoptosis,
transport, energy pathways and cell growth/maintenance. D) Functional enrichment analysis of diabetic retina
EV miRNA species determined significant increases in percentage of genes correlated to biological processes
including apoptosis, signal transduction and transport. FunRich was used to perform hypergeometric test with
Benjamini-Hochberg method correction.

species shared between EVs from both samples, 21 species present only in diabetic
retina EVs, and 7 only identified exclusively in non-diabetic control retina EVs (Figure
22A). Next, using FunRich miRNA enrichment software, enriched biological pathways
associated with diabetic or non-diabetic EV miRNA species were identified. There were
no pathways significantly enriched for the 7 miRNAs found only in non-diabetic EVs.
Several pathways were significantly enriched for diabetic EV miRNA species including
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endothelins (35.7%), VEGF and VEGFR signaling network (36%) TRAIL signaling
(37.1%), proteoglycan syndecan mediated signaling events (37.4%) and plasma
membrane estrogen receptor signaling (36.7%) (Figure 22B). Next analysis was
performed to determine enrichment of cell biologic processes associated with diabetic
and non-diabetic EV miRNA. Cell biologic processes with significant fold enrichment
included apoptosis, energy pathways, cell growth/maintenance and transport and protein
metabolism. In contrast, biologic processes including metabolism, cell communication
and signal transduction were depleted (Figure 22C). Analysis was performed for the
biological processes of all diabetic (321) and non-diabetic (307) EV miRNA species to
identify significant enrichment between the two sample groups. Significant enrichment
was detected for processes including signal transduction (23.6%), transport (7.7%) and
cell communication (21.9%) for both samples, but apoptosis (1.5%) was significantly
enriched only in the diabetic sample population. (Figure 22D).

Figure 23. Retinal EV miRNA has both weak and strong predicted interactions with target genes.
A) Interaction network of miRNAs exclusive to non-diabetic retina EVs and target genes. B) Diabetic
retina EVs network diagram reveals strong miRNA –target gene interactions indicated by green lines.
orange = genes targeted by more than 2 miRNAs, blue = genes targeted by 2 miRNAs and brown =
miRNAs, Green lines = direct interactions, blue lines = indirect interactions.

from miRNA species identified in retinal EVs, miRTarget Link Human database was used
and network maps generated. The database uses a strong and weak evidence-based
system for identifying targets; strong interactions are supported by experimental methods
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such as reporter gene assays while weak interactions are supported by experimental
methods such as microarrays. For non-diabetic EV samples, (n=7) exclusive miRNAs, 8
genes were found to be targeted by 2 or more miRNAs each with weak interactions
(Figure 23A). For the exclusive diabetic EV miRNAs (n=21) 520 target genes were
identified that were targeted by 2 or more miRNAs with strong and weak interactions
(Figure 23B). A total of 8 diabetic EV miRNAs including hsa-miR-197-3p, hsa-miR-365a3p, hsa-miR-1291, hsa-miR-138-5p, hsa-miR-766-3p, hsa-miR-574-3p, hsa-miR-10b-3p
and hsa-miR-429 showed strong interactions with target genes. The strong interactions
are presented in the network diagram and shows that some miRNAs target the same
genes (Figure 23B). The 8 miRNAs in diabetic retina EVs were predicted to target the
following genes with strong interactions: TUSC2, PMAIP1, CCND1, BCL2, BAX, ACVR1,
KRAS, SHC1, ABCC1, TERT, 1GF1R, SIRT1, CCND3, HIF1A, BLCAP, EZH2, ZEB2,
VIM, HNF4A, RAC1, EP300, RXRA, CCNA2, XIAP, KLHL20, WDR37 AND HOXB5.
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Type
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Name

Number
of hits

Expected
number of
hits

q-value

1.71E04
3.67E04

An

over-representation
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ed
enrich
ed

1

FoxO family signaling

11

1.72

2
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2.774
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ed
enrich
ed
enrich
ed
enrich
ed

3

8

1.194

0.0013

11

2.493

0.0019
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0.0021

7
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0.0044
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7

9
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ed

8

Validated targets of CMYC transcriptional
activation
Class I PI3K signaling
events mediated by Akt
E2F transcription factor
network
Regulation of
retinoblastoma protein
E-cadherin signaling in
the nascent adherens
junction
Signaling events
mediated by HDAC Class
I
Insulin Pathway

7

1.404

0.0105
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8
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0.0105

Interaction Database. A
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ed

10

6
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ed
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ed
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ed
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Role of Calcineurindependent NFAT
signaling in lymphocytes
Trk receptor signaling
mediated by PI3K and
PLC-gamma
p73 transcription factor
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IL2 signaling events
mediated by PI3K
Class I PI3K signaling
events
IGF1 pathway

9

2.493

0.0162
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as
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6

1.229

0.0226

(Table

3).

Over-

6

1.369

0.0305

representation

analysis

5

0.948

0.0305

5

0.948

0.0305
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6
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0.0305

diabetic
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ed
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ed

17

IL2 signaling events
mediated by STAT5
Signaling events
mediated by HDAC Class
III
Coregulation of Androgen
receptor activity
Lissencephaly gene
(LIS1) in neuronal
migration and
development

7

1.966

0.0425

targets and no significant

5

1.053

0.0438

enrichment

4
5
6

8

12
13
13
13
13

18

Table 3. Diabetic EVs miRNA show enrichment for pathways
involved in DR. Overexpression analysis using GeneTrail21 shows
enrichment for pathways involved in DR including insulin signaling, PI3K
A
signaling, IGF1, E2F, E-cadherin and retinoblastoma protein.

analysis was performed
for the 520 identified
target genes of diabetic
retina EV miRNAs to
identify

significantly

NCI-Pathway

performed
EV

nonmiRNA

was

predicted.

network diagram was

generated to show enriched pathways associated with miRNAs present exclusively in
diabetic retina EVs and connections between biological processes (Figure 24). Diabetic
retina EV miRNA gene enrichment analysis predicts biological processes associated with
DR including insulin pathway, regulation of retinoblastoma protein, e-cadherin signaling,
PI3K signaling and C-MYC transcription.
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Figure 24. Diabetic EVs miRNA target genes
show enrichment for pathways involved in
DR. Enriched pathways associated with
miRNAs present exclusively in diabetic retina
EVs show pathways involved in DR including
insulin signaling, PI3K signaling, IGF1, E2F, Ecadherin and retinoblastoma protein.

In summary NGS analysis of miRNA contained in diabetic retina EVs predicts targeting
and regulation of pathways associated with DR pathogenesis. The correlation of disease
related pathways to diabetic retina EV miRNAs was not seen for non-diabetic EV miRNA
species. The data support a role for EV signaling in disease processes associated with
diabetic retinopathy. Future studies may build on this data to establish the functional
significance of EV transported miRNA in diabetes and diabetic retinopathy.

4.7. Discussion
This is the first study to report release of EVs from neural retina. Other investigators have
shown release of EVs in the vitreous humor, aqueous humor, and from retinal astrocytes,
RPE or Müller glial cells.

136,148,196-199

Our TEM and Nanosight analysis morphology and

size range data support that retinal EVs have characteristics of both exosomes and
microvesicles. FunRich analysis showed site of expression to be primarily within the
retina, with a subset of EV proteins identified as critical for the visual cycle. Rhodopsin is
a photosensitive pigment in the rod cell phototransduction cascade.200,201 Recoverin is a
Ca2+ binding protein found in photoreceptors, involved in photopigment phosphorylation
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and the recycling process.202-204 Other identified retinal EV proteins include retinal
pigment epithelium-specific protein 65kDa (RPE65), phosducin, and phosphodiesterase
6B (PDE6B), each integral to the visual cycle.205,206 Other key proteins such as
Interphotoreceptor matrix proteoglycan 1, retinoschisin 1 and Membrane protein,
palmitoylated 2 are key structural components in the RPE- photoreceptor matrix.

207-209

Signaling proteins involved in synaptic transmission were also identified including coronin,
Unc-119 homolog, guanine nucleotide binding protein (G protein) and gamma
transducing activity polypeptide 1. 210-213

Bioinformatics comparison of protein signatures between diabetic and non-diabetic retina
showed significant fold differences in biological processes associated with DR for diabetic
retina, including regulation of cell shape, lipid metabolism and mitochondrial transport
(Figure 20A). Change in retinal cell integrity and structure are hallmarks of DR. Studies
by van Dijk et al. have shown that patients with minimal levels of DR already show thinning
of the inner nuclear layer (INL) when compared with non DR individuals, supporting a
neurodegenerative effect from DR.214,215 Other studies report that reduced thickness is
also evident in the ganglion cell layer using similar experimental conditions 216. One of the
most well-known mechanisms in DR development is the change in the blood retinal
barrier and more specifically the dysregulation of endothelial cells in capillaries.217-220
Loss of integral vascular membrane and structural properties lead to alterations in cell
shape and permeability, leading to development of microaneurysms, retinal edema and
hemorrhaging. The mitochondrial membrane is also subject to structural changes as
hyperglycemia affects integral proteins that allow the release of cytochrome c, a known
apoptotic regulator.221 Lipid metabolism is significantly affected in DR which may lead to
a condition known as dyslipidemia, in which faulty insulin signaling causes increased
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levels of both triglycerides and low density lipoproteins (LDL) and reduced levels of high
density lipoproteins (HDL). Increased levels of fatty acids and cholesterol creates an
inflammatory response in the retina.

222-226

Stable mitochondrial activity within the retina

is crucial and alterations lead to an increase in reactive oxygen species (ROS) that lead
to oxidative damage.

227

Elevated levels of glucose in the diabetic retinal environment

dysregulate mitochondria membrane dynamics leading to increased ROS transport and
decreased functional protein transport needed for normal mitochondrial function. 228-230

Biologic processes correlated to proteins in diabetic retina EVs strongly associated with
DR pathology include carbohydrate signaling, wound healing, cell proliferation and
immune responses (Figure 20B). A central pathway in DR pathogenesis is the polyol
pathway, which is activated by hyperglycemia. In this process, elevated glucose is
converted into sorbitol via NADPH as a cofactor and NADPH concentrations are
decreased lowering levels of the antioxidant glutathione, resulting in increased oxidative
stress 231-233 . Elevated levels of glucose also lead to the formation of advanced glycation
end products (AGEs) which further advance DR pathogenesis.234,235 This pathway may
be a basis for the diabetic retina and EV gene ontology enrichment we see for
carbohydrate mediated signaling. Another set of biological processes that are enriched in
diabetic retina EVs are wound healing and cell proliferation, which are severely
compromised in diabetic individuals. Angiogenesis plays a key role in the advancement
of DR and is associated with wound healing. Hypoxia-induced endothelial cell dysfunction
activates angiogenic pathways that recruit molecules such as VEGF-A and fibroblast
growth factor (FGF), stimulating the growth and proliferation of new blood vessels. While
angiogenic properties are increased in DR, diabetic patients are known to suffer from
delayed wound healing associated with hyperglycemia.236-238 These observations offer
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some insight into the elevated protein signatures enriched for proliferation and wound
healing.

A central question of our study is what role EVs might play in the pathogenesis of DR.
One way to address this is by evaluating molecular functions correlated with proteins
upregulated (n=37) in diabetic retina EVs and their association to DR (Figure 14A).
Hypoxia inducible factor-1 (HIF-1) was identified as a highly correlated molecular function
and is a key component in DR. The mechanism of action of HIF-1 involves the
development of retinal hypoxic ischemia.239,240 These changes create an environment in
which capillary cells become occluded or leaky, resulting in poor blood flow to retinal
tissues.241 This hypoxic condition triggers the release of HIF-1, a proangiogenic
transcription factor that stimulates the production of angiogenic molecules such as
angiopoietin, erythropoietin and VEGF. These molecules are responsible for the aberrant
growth of blood vessels in DR.242-245 Impairment of retinal blood flow and oxygen is
triggered in early DR stages due to activated inflammatory responses and endothelial cell
dysfunction.

VEGF signaling and its associated receptors were also found in the top percentile of
enriched molecular functions whose role in the pathogenesis of DR has been well defined
246,247

. Approximately 67% of diabetic retina EV proteins were linked to the Arf6

downstream signaling molecular function. This signaling pathway is involved in VEGF
receptor signaling. Studies conducted by Zhu et al. have shown that Arf6 interacts with
VEGFR2 signaling pathway by activating two key guanine nucleotide exchange factors
(GEFs), ARNO and GEP100, that are responsible for VEGFR2 internalization and
recycling. 248-250
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Another DR associated function correlated to diabetic retina EV proteins is signaling by
focal adhesion kinases, which play a role in RGC survival during DR stress.251,252 The
extracellular matrix (ECM) is a critical component for cell signaling and is involved in
regulating cell growth, apoptosis, migration and survival.

253

During ischemia, as occurs

in DR, RGCs are susceptible to apoptotic factors such as matrix metalloproteinase (MMP9) and studies have shown pro-survival factors are secreted through β1 integrin receptor
by activation of the focal adhesion kinase mechanism.

Also associated with diabetic retina EV protein is the phosphatidylinositol 3-kinase (PI3K)
signaling

network,

which

is

critical

to

cell

proliferation,

apoptosis,

and

communication254,255. The PI3K/AKT activated network is involved in DR pathogenesis
through

proangiogenic

endothelial

cell

survival

and

upregulation

of

integrin

structures.256,257 The PI3K/AKT network facilitates a multifaceted angiogenic response
by activating factors including HIF-1, Ephrin B2, Slit-2, angiopoetin 1 and nitric oxide
which promote endothelial cell migration and guide membrane dynamics for vascular
growth.258-265

A set of upregulated proteins shared between diabetic retina and EVs correlate closely to
neuroprotection of disease progress during DR (Figure 13A). All three upregulated
proteins identified overlapping between diabetic retina and EVs are Annexin A1 (ANXA1,
Ceruloplasmin (CP) and Low density lipoprotein receptor-related protein 1 (LRP1).
ANXA1 has a neuroprotective role and functions as an inhibitor of inflammation by
restoring homeostatic conditions through AKT signaling.

266-269

The other identified
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proteins are CP and LRP1, which promote DR progression through oxidative stress and
angiogenesis. 270-277

The downregulated proteins (n=27) shared between diabetic retina and their EVs were
investigated for correlated DR processes (Figure 14). DR pathogenesis involves
apoptosis and malfunctioning of retina photoreceptors, glia and RPE, leading to disruption
in the process of visual signal processing.

278-280

Another process, retrograde

neurotrophin signaling, modulates neural synaptic plasticity and survival.281 There are
four classes of neurotrophins; nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4), and altered expression
levels have been reported for each during DR pathogenesis282. Decreased levels of NGF
and BDNF have been detected in serum, vitreous and aqueous humor during DR.283-285
DR-associated retinal degeneration has been shown to occur through decreased
activation of TrkA levels that increase p75 NTR, activating pro-apoptotic p38 mitogenactivated protein kinase (MAPK) signal.286 Similar studies have shown imbalance of
proNT3/NT3

leading

to

upregulation

of

p75NTR

resulting

in

photoreceptor

degeneration287,288. These imbalances also play a role in retinal inflammation and
vascular permeability contributing to DR283,284. In summary, this analysis suggests that
diabetic retina and EV protein species’ presence and abundance can be analyzed for
correlation to disease state and pathologic processes.

The analysis of miRNAs contained in diabetic retinal EVs provides data which describes
potential molecular mechanisms and biomarkers of DR pathogenesis. Similar, to our
proteomic studies, diabetic EV miRNA correlates to DR pathways, including VEGF
signaling, endothelins, TRAIL and estrogen receptor signaling, which are all critical
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components in DR disease progression (Figure 22B). A miRNA of with potential
association to DR pathogenesis and found across our samples is hsa-miR-365a-3p which
interacts with BAX, BCL2 and SHC1 (Figure 23B). Previous studies have shown that mir365a-3p is involved in DR pathogenesis through the Timp3 pathway by Müller cell gliosis,
which contributes to oxidative stress and neuronal death. 289 It has been demonstrated
that circulating hsa-miR-365a-3p is linked to increased Hba1c concentrations in type 1
diabetics.290 Target genes Bax and SHC1 are pro-apoptotic proteins that play a role in
DR progression through mitochondrial dysfunction.

291-293

It is plausible that hsa-miR-

365a-3p has a neuroprotective function as it inhibits pro-apoptotic proteins such as Bax
and SHC1. Data presented here suggests that a number of miRNAs present in diabetic
retina EVs target genes known to play a role in DR development and progression
including HIF1, RXRA, VIM, RAC1

242,294-298

Further analysis may elucidate functional

significance of miRNA species identified in diabetic retinal EVs.

4.8. Materials and Methods

4.8.1. Human retina isolation and culture
All experiments were approved by and performed in compliance with the City University
of New York, Lehman College (IRB). Cadaver whole eyes or shells were obtained through
the New York Eyebank for Sight Restoration or the National Disease Research
Interchange. The anterior segments were cut away at the ora serrata, vitreous and RPE
removed from neural retina. Neural retinas were cultured in 6-well plates in 5mL of
Dulbecco's Modified Eagle Medium (DMEM) media plus 10% exosome free fetal bovine
serum (FBS), 1% penicillin streptomycin and 0.2% nystatin and cultured at 37ºC. Retina
conditioned media and retina were collected after five days for analysis.
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4.8.2. EV isolation from human retina
Conditioned media was collected from 6-well plates and EVs
untracentrifugation as previously described

188.

isolated using

Media was centrifuged at 300 × g for

10 min at 4 °C to pellet cell debris. Briefly, supernatant was transferred to an
ultracentrifuge tube (Beckman Coulter), spun at 10,000 × g for 20 min using 60Ti rotor
(Beckman Coulter ultracentrifuge) at 4 °C; supernatant was centrifuged at 100, 000 × g
for 70 min to pellet the EVs. All centrifugation was performed at 4 °C to minimize
degradation of EVs. EVs were suspended in phosphate-buffered saline (PBS) and stored
at −80 °C for analysis.

4.8.3. Nanosight analysis
EV diameter and concentration were assessed using the NanoSight NS500 system

299.

Retina conditioned media was collected at 5 days of culture and transferred to centrifuge
tubes. Media was centrifuged at 300 x g for 5 minutes, supernatant transferred to a
centrifuge tube and spun at 500 x g for 10 minutes, then at process repeated and spun
at 3000g for 20 minutes. Control non-conditioned media was processed using identical
steps. Supernatant was diluted at 1:20 in PBS and 1ml was used for NanoSight analysis.
Nanoparticle Tracking Analysis (NTA) software 2.3 was used to track trajectories and
diameters of nanoparticles. Results are displayed as frequency sized distribution graphs
describing the number of particles per milliliter. The concentration of released EVs was
calculated to determine the average number of EVs with standard deviation in conditioned
media compared to control and analyzed using a Student’s t-test.
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4.8.4. Transmission Electron Microscopy (TEM)
EVs isolated from conditioned media were fixed in 2.5% glutaraldehyde with 4%
paraformaldehyde (EM grade) for 2.5 hours and washed in PBS for 24 hours. EVs were
post-fixed in osmium tetraoxide for 30 min, washed with distilled water and subsequently
dehydrated using increasing ethanol concentrations (70%, 85%, 95% and 100%), each
for 10 minutes. Sample dehydration was followed by immersion in propylene for 20
minutes twice. Samples were infiltrated with a 1:1 mixture of propylene oxide and Spurr’s
Resin for 1 hour, left in 100% Spurr’s Resin overnight. Samples were then embedded in
beem capsules using fresh Spurr’s Resin at 70°C for polymerization. Excess resin was
trimmed and 90 nm sections of samples were made using a Leica Ultramicrotome.
Sections were placed on 200 mesh copper grids, stained with saturated uranyl acetate in
50% ethanol for 6 minutes, rinsed in water and stained for 90 seconds in lead citrate.
Grids were then rinsed in water, dried on filter paper and viewed under a Fei Tecnai
transmission electron microscope operated at 80 kV. Images were obtained using an
AMT camera with AMT digital software.

4.8.5. Retinal RNA labeling and EV RNA cargo Transfer Analysis
Using the culture and isolation methods described above, the RNA specific dye
SytoRNA Select (Invitrogen) was used on whole human retina with minor modifications
to manufacturer’s protocol. Retinas were placed in a 2.5uM solution of dye and incubated
at 37°C, 5 CO 2 for one hour and then rinsed three times with fresh media. SytoRNA
labeled retina were then incubated in the TRITC fluorescent lipophilic dye PKH26 (Sigma)
according to manufacturer’s instructions. Retina was placed in 500uL diluent and
transferred to a 4 ×10 -6 M dye solution, and incubated at room temperature for 15
minutes on an orbital shaker. 1 mL of HI-FBS was used to quench labeling. SytoRNA and
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PKH26 labeled retina was washed in fresh culture medium 3X and transferred to 6 well
plates containing fresh media.

4.8.6. Transwell Extracellular Vesicle Diffusion Culture
Human retinas were collected as described above, lightly dissociated by trituration, and
cultured in 12 well glass bottom plates (MatTek corporation). Whole retina stained with
SytoRNA Select (Invitrogen) and PKH26 (Sigma), as described above, were cultured in
Transwell inserts with 0.4μm pore PET membranes above non-labeled dissociated retina
and co-cultured for five days. Double SytoRNA (green) RNA and PKH26 (red) lipid
labelled EVs released by adult retina diffused through the transwell membrane pores and
were imaged contacting cells on glass-bottom wells.

4.8.7. Super resolution Imaging of retinal cells containing Transferred EVs
Following transwell diffusion of EVs double labeled with SytoRNA (RNA) and PKH26
(lipid) (above)target adult retinal neurons from glass bottom wells containing adherent or
internalized EVs were fixed with 4% PFA and mounted with DAPI Prolong Gold mounting
media for imaging. Multichannel structured illumination microscopy (SIM) images were
acquired using a Nikon Structured Illumination N-SIM system on an inverted Nikon
ECLIPSE Ti-E equipped with a 100× 1.49 NA objective. Multicolor fluorescence was
generated using diode lasers (488, 561 and 647 nm). Z stack images were acquired using
the electron-multiplying CCD cameras (Andor iXon3 DU897) 512 × 512 pixel frame size.
Three reconstruction parameters (Illumination Modulation Contrast, High Resolution
Noise Suppression and Out of Focus Blur Suppression) were extensively tested to
generate consistent images across experiments without abnormal features or artifacts

66

and producing the best Fourier transforms. The acquired images were then processed
using Nikon Elements software. 3D reconstruction was generated
using Imaris software (Bitplane).

4.8.8. Retina and extracellular vesicle RNA isolation
Total RNA was extracted and purified from retinal tissue and EV pellets using the Trizol
reagent according to the manufacturer's protocol (Thermo Fisher). Trizol was added, 6ml
(retina) / .04ml (EVs), and incubated for 5 minutes. Chloroform was then added 0.2mL /
.08ml, samples incubated for 3 minutes, then centrifuged for 15 minutes at 12,000 × g at
4°C. The aqueous phase was transferred to a new tube and isopropanol added
0.5mL/0.2ml, per 1 mL and incubated for 10 minutes. Samples were centrifuged for 10
minutes at 12,000 × g at 4°C. Supernatant was discarded with a micropipettor and pellet
resuspended in 75% ethanol per 1 mL of Trizol reagent used. Samples were vortexed
briefly and centrifuged for 5 minutes at 7500 × g at 4°C. Supernatant was discarded and
RNA pellet air dried for 5–10 minutes. RNA was diluted in 50ul of Nuclease free water
and stored at -80°C.

4.8.9. Protein Isolation
Protein was isolated from retinal tissue Pierce lysis buffer (Thermo Fisher) with 1%
protease inhibitor and 1 % phosphatase inhibitor. For EV protein isolation, centrifuged
and pelleted EVs were suspended in 200ul PBS and using the Pierce lysis buffer protocol.
Protein concentrations were obtained using the bicinchoninic acid assay (BCA) assay
(Thermo Fisher).
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4.8.10. WST analysis
Retina were cultured as described above at 37ºC, 5% CO2 and viability assessed using
water soluble tetrazolium Salt (WST) assay (Sigma). Conditioned media (100ul) was
collected from three wells every 24hrs for 120hrs and analyzed for viability. Colormetric
analysis was performed in 96-well plates, by mixing 10ul of WST reagent with 100ul of
experimental media and incubating at 37ºC, 5% CO2 for 4 hours. WST absorbance was
then read at 480nm as an indicator of cell number and viability.

4.8.11. Mass spectrometry
Whole cell lysate and EV-enriched samples from human retina were denatured in 8M
urea, reduced with 10mM DTT, and alkylated with 50mM iodoacetamide. This was
followed by proteolytic digestion with endoproteinase LysC (Wako Chemicals) overnight,
and with trypsin (Promega) for 6h at room temperature. The digestion was quenched with
2% formicacid and resulting peptide mixtures were 44. Samples were dried and
resolubilized in 2% acetonitrile and 2%formic acid. Approximately 1μg of each sample
was injected for analysis by reversed phasenano-LC-MS/MS (Ultimate 3000 coupled to
a QExactive Plus, Thermo Scientific). After loading on a C18 trap column (PepMap, 5μm
particles, 100μm x 2cm, Thermo Scientific) peptides were separated using a 12 cm x
75μm C18 column (3μm particles, Nikkyo Technos Co., Ltd. Japan) at a flow rate of
200nL/min, with a gradient increasing from 5% BufferB (0.1% formic acid in acetonitrile)
/ 95% Buffer A (0.1% formic acid) to 40% Buffer B / 60%Buffer A, over 140 minutes. All
LC-MS/MS experiments were performed in data dependent mode with lock mass of m/z
445.1200345. Precursor mass spectra were recorded in a 300-1400m/z range at 70,000
resolutions, and fragment ions at 17,500 resolutions (lowest mass: m/z 100). Up to twenty
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precursors per cycle were selected for fragmentation and dynamic exclusion was set to
60 s. Normalized collision energy was set to 27.

4.8.12. Protein profiling analysis
Mass spectrometry data were searched against a human database using MaxQuant
(version 1.5.0.30 45). Oxidation of methionine and N-terminal protein acetylation were
allowed as variable modifications, while all cysteines were treated as being
carbamidomethylated. Precursor mass tolerance was set at 4.5ppm while a 20ppm
tolerance was allowed for fragment ions. Two missed cleavages were allowed for specific
tryptic search. The “match between runs” option was enabled. False discovery rates at
the protein and peptide level were set to 1%.

4.8.13. Proteome Discoverer Analysis
Identified peptides were filtered using 1% False Discovery Rate (FDR) and Percolator.
Proteins were sorted out according to highest area. The area is calculated based on the
3 most abundant peptides for the respective protein. Proteins not detected or present in
low amounts are assigned an area zero. Data were extracted and queried against the
human database using Proteome Discoverer and Mascot. Protein abundance was
analyzed using area abundance normalized against control media absent of tissue. The
normalized values were then analyzed for differences in fold changes among
experimental samples.300,301

4.8.14. Quantitative PCR analysis
Total RNA (1 µg) was reverse-transcribed to produce complementary DNA (cDNA) using
the New England Biolabs Protoscript AMV First Strand cDNA Synthesis Kit according to
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the manufacturer’s protocol. Briefly, isolated RNA was mixed with d (T) 23 primer and
denatured for 5 min at 70°C.

AMV reaction mix buffer enzyme mix of reverse

transcriptase and RNase inhibitor was added to the sample and incubated at 42°C for 1
hour. The AMV enzyme was inactivated via incubation at 80°C for 5 min. The cDNA
product was diluted with 30μl nuclease-free water and analyzed using SYBR Green ER
qPCR Supermix. According to the iCycler protocol, 12.5µL of SYBR GreenER qPCR
Supermix, 0.5 µL of forward and reverse primers and 1µL of cDNA template were
combined and DEPC water added to bring the volume to 25µL. Samples were prepared
in triplicates and mixed in a PCR plate followed by amplification and melting curve
analysis using a Bio-Rad iCycler.

4.8.15. Next Generation Sequencing analysis
For NGS of retinal EVs, small RNA Libraries were generated using a NEBNext® Multiplex
Small RNA Library Prep Set for Illumina (NEB, Ipswich, MA) (PMC5975555). For
exosomal RNA isolated from cell culture media, approximately 1 ng was used as input for
library generation. Three biological replicates were used for each of the experimental EV
media. The Multiplex Small RNA Library prep set has an input concentration range and
does not rely on starting the library using an equal RNA amount. The libraries were
prepared according to the manufacturer’s instructions. The amplified libraries were
resolved on Novex® 6% TBE Gels (Thermo Fisher, Waltham, MA). Library fragments
were excised and further purified using a RNA Clean-up and Concentration Micro-Elute
Kit (Norgen Biotek, Thorold, Ontario). The indexed libraries were quantified using the High
Sensitivity DNA Kit (Agilent, Santa Clara, CA). All libraries derived from EVs were pooled
together for a final pooled library at a final concentration of 4nM. Normalization of libraries
after size selection is the used method for small RNA Sequencing. The libraries were
70

pooled using equal molarities from the NGS library of each sample. The pooled library
was then sequenced on an Illumina MiSeq using version 3 reagents by Norgen Biotek
Corp. A small RNA expression profile was generated from the resulting FASTQ files using
the exceRpt small RNA-seq pipeline [56]. Sequencing was quality controlled using a
Nanodrop ND/1000 spectrophotometer.

Read mapping and small RNA annotation
The sequence raw data from the Illumina HiSeq 4000were converted to fastq format. Files
were then used in the Genboree Workbench’s exceRpt small RNA-seq pipeline
(version 4.6.2) for read mapping to the hg38 human genome version [66]. This allowed
for a single mismatched base down to 18 nucleotides. After adapter trimming, read quality
was assessed by FASTQC to filter out reads with a quality score lower than 30 on the
PHRED scale. Reads were first mapped to the UniVecand human ribosomal RNA (rRNA)
sequences to exclude them before mapping to databases of miRBaseversion 21,
gtRNAdb and piRNABank to assign reads to miRNAs, tRNAs and piRNAs, respectively.
Identified t RNAs are tRNA-derived RNA fragments due to the fact that the library insert
size is below 50 nt. Remaining sequences were then annotated to gencode version
24(hg38) which includes protein coding transcripts (protein_coding), mitochondrial rRNA
(Mt_rRNA), mitochondrial tRNA
nucleolar

RNA

(snoRNA),

(Mt_tRNA),

long

small

inter-genic

nuclear

noncoding

RNA(snRNA), small
RNA

(lincRNA)

and

miscellaneousRNA (misc_RNA).

Data analysis
Raw read counts obtained from the Genboree Work-bench’s exceRpt small RNA-seq
pipeline were further analyzed using R (version 3.5.2). The following R packages were
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used in the analysis: RnaSeqGeneEdgeRQL (version 1.4.1) for counts per million (CPM)
filtration and normalization by using trimmed mean of M-values (TMM) [67], ggfortify
(version 0.4.5) and Complex Heatmap (version 1.20.0) for principal component analysis
(PCA) plot and heat maps based on the filtered and normalized data, respectively. Venn
Diagram (version 1.6.20) was used to illustrate Venn diagrams.

4.8.16. Bioinformatics analysis
Functional enrichment analysis was done using the FunRich software for both protein and
miRNA enrichment analysis. Protein classifications were analyzed using the Panther
Gene Ontology classification system. miRNA targeting network were analyzed using
miRTargetLink Human database.167,302-304

5. Human urinary EVs as a prognostic marker for diabetic retinopathy

5.1. Characterization of human urinary EVs from non-diabetic, diabetic and
diabetic retinopathy patient samples

Human urinary EVs were analyzed from non-diabetic, diabetic and diabetic retinopathy
patients to determine their molecular cargo and potential as a prognostic marker of DR
onset

and

pathogenesis.

EVs

identified in vitreous fluid previously
have shown function associated with
normal visual processing. EVs have
Figure 25. Human urine EVs from diabetic patients
contain canonical markers for exosomes and genetic
cargo. Immunogold TEM imaging of EVs isolated from
human urine label for A) CD63 and B) TSG 101. A,B Scale:
100nm. C) qPCR analysis reveals the presence of CD63
and urinary markers AQP2 and Cyclophillin A.

also

been

containing
associated

detected

in

molecular
with

organ

urine,
cargo
system
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processes and with CNS disease progression

305,306

To determine if urine EVs contain

molecular cargo from retina and could serve as prognostic markers for DR, urine EVs
were analyzed from non-diabetic, diabetic without DR and severe diabetic with DR patient
urine. Urine EVs were characterized for differences in ultrastructure, concentration and
molecular cargo. EVs were isolated from patient urine using ultracentrifugation as
described above. Canonical EV protein marker identification was established via
immunogold TEM for CD63 and TSG101 (Figure 25A,B ). qPCR was performed to
analyze the presence of transcripts for the EV markers AQP2, CD63 and Cyclophillin A
(Figure 25C). This data indicates that EVs can be isolated from patient urine with
detectable mRNA cargo.

5.2. Ultrastructure

of

EVs

released from non-diabetic
and diabetic DR human urine
To understand differences in EV
distribution
diabetic

between

and

DR

non-

urine

we

performed Nanosight Tracking
across patient samples. Figure
26A-B shows an EV density plot
Figure 26. DR urine contains larger and more concentrated
EVs. A) An NTA plot of non-diabetic urine EVs showing intensity vs
size and B) DR urine EVs with an increased intensity vs size
distribution. C) The average size of non-diabetic urine EVs (210.1 ±
7.316, n=3) was significantly smaller that diabetic urine EVs (230.1
± 4.07, n=3), one-tailed T-test, p=0.0147. D) The average
concentration of non-diabetic urine EVs (4.63 x108± 4.20 x 107,
n=3) was significantly smaller than diabetic urine EVs (6.83 x 108 ±
9.23 x 107, n=3), one-tailed T-test, p=0.0259. E) EV concentrations
were shown to be significantly higher for DR urine EVs at specific
diameter ranges analyzed including 0-99, 100-199, 200-299, 300399, 400-499, 500-599 (p=<0.0001, each) and 600-699 (p=0.0197).

distribution

of

non-diabetic

and DR urine, respectively.
Figure 26B shows a higher
EV

concentration

indicating
particles

either
are

in

DR
more

released

or
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fewer are absorbed, with a wider range of diameters compared to non-diabetic urine. The
average size of particles released from DR urine (230.1nm ± 4.07, n=3) was significantly
larger than non-diabetic (210.1nm ± 7.316, n=3), one-tailed t-test, p=0.0147. In Figure
26D, the average urine EV concentration was significantly smaller in non-diabetic (4.63
x108 ± 4.20 x 107, n=3) compared to diabetic retinopathy (6.83 x 108 ± 9.23 x 107, n=3)
samples, one-tailed t-test, p=0.0259. Analysis was then performed to identify EV
diameters and concentrations potentially unique to either non-diabetic or DR samples
Figure 26E. The DR urine samples had a significantly higher number of particles being
released at all size increments. This pattern of higher particle release has been shown in
previous studies of diseased conditions.307 Analysis showed that for non-diabetic and DR
samples EVs are concentrated in the 30nm-200nm size range with greater overall
diameters in DR samples.

5.3. Proteomic characterization and content of non-diabetic and DR human urine
EVs
To characterize
Figure 27. Distribution of protein
species between non-diabetic and
DR EVs. A) Venn diagram showing
distribution of proteins found in
severe DR (1157) and non-diabetic
DR (76) with an overlap of 1044
protein signatures. B) Venn diagram
showing overlap with Vesiclepedia
database of known EV proteins. N=2
for both sample groups

the

proteomic
differences

between

non-

diabetic and DR
patient

urine

EVs,

mass

spectroscopy
was performed.
The

analysis

identified 2221 total proteins in DR urine EVs and 1120 in non-diabetic urine EVs. (Figure
27A). 1157 protein species were identified in DR urine EVs alone, 76 in non-diabetic and
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1044 shared (For list of proteins see Supplementary Figure 2a). Non-diabeticand
DR EV proteins were cross referenced with the Vesiclepedia human protein database
and 1670 matching species were identified, with 44 only from DR EVs, 760 only from nondiabetic EVs and 866 shared Figure 27B. Novel EV proteins in our samples that did not
match proteins in the Vesiclepedia database include 29 from DR alone, 2 from nondiabeticand 13 shared. FunRich functional interaction analysis was performed on the 29
novel DR urine EV proteins and enriched pathways identified (Figure 28). The most highly
correlated pathways associated with novel DR EV proteins included VEGF signaling,
Integrin family surface interactions, TRAIL signaling, insulin and ErBb1 signaling
pathways. Network analysis of the 2 novel EV proteins in non-diabetic urine showed no
significant network enrichments. Finally, interaction analysis for the 13 novel EV proteins
shared between non-diabetic and DR show a primary association to metabolism
pathways (Figure 29).

Figure 28. Networks correlated to novel EV proteins in DR samples. FunRich interaction map
showing enriched pathways and gene count for proteins found in DR EVs and not in Vesiclepedia
database.
e.
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Figure 29. Interaction map showing networks associated with shared EV proteins. Comparisons
were made between DR and non-diabetic samples.

Next, analysis was performed to predict the functions of proteins found within DR urine
EVs and how they may contribute to DR pathogenesis. We used functional enrichment
analysis to find the molecular functions associated with these proteins. (Figure 30A). The
highest percent associated functions were catalytic activity (8.1%), transporter activity
(5.9%) and cell adhesion molecule activity (3.8%). Next, the biological pathways
associated with severe DR urine EV proteins were then mapped to DR pathways. We
found the top percentages to be metabolism (29.8%), diabetes (11.8%) and insulin
synthesis and processing (9.5%) (Figure 30B). Other enriched pathways included L13a
mediated silencing which regulates ceruloplasmin levels 308 and eukaryotic translation
mechanisms which have been shown to contribute to DR.309 These results suggest that
proteins isolated from severe DR urine EVs may be involved in the pathogenesis of DR.
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A

B

Figure 30. Severe DR EV proteins have predicted functions and pathways associated with DR
pathogenesis. A) Molecular functions associated with proteins identified in DR EVs. Highest percent
associated molecular functions include catalytic activity 8.1% and structural constituent of ribosome
3.7%. B) DR EV proteins associate pathways with predicted involvement in DR pathogenesis including
diabetes pathways (11.8%), insulin synthesis and processing (9.5%), metabolism (29.8%) and
translation (9.2%). FunRich was used to perform hypergeometric test with Benjamini-Hochberg method
correction.

A central goal of this work was to determine if retinal DR EV protein signatures could be
detected in urine and provide information as a prognostic for DR onset or progression. To
assess this, retina DR EV
Figure 31. Urine DR EVs and
retina DR EVs contain
shared
proteins.
Venn
diagram showing 96 unique
protein signatures identified in
both urine DR EVs and DR
retina EVs.

proteins were compared with
urine DR EV proteins and a
total of

96

proteins

were

identified as shared between both samples (Figure 31). (For list of proteins see
Supplementary Figure 2b). The 96 proteins were analyzed for cellular component and
showed enrichment for exosomes (45.6%), mitochondria (38%) and lysosomes (58.2%)
(Figure 32A). Mitochondria and lysosomes play critical roles in apoptosis and autophagy
during DR.310-312

Biological pathways correlated to the 96 shared proteins included metabolism (29.5%),
integrin cell surface interactions (20.5%), VEGF signaling (18.2%), Arf6 signaling
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(18.2%), EGF receptor signaling (18.2%) and mTOR signaling pathway (18.2%) (Figure
32B), each associated with DR pathogenesis. 43 shared proteins were identified with 4
fold or greater upregulation in both urine DR EVs and retina DR EVs (Figure 33) (For list
of proteins and functions see Supplementary Figure 2c and Supplementary Table 1d).

A

B

Figure 32. Cell component and functional associations of 96 proteins shared between urine
DR EVs and retina DR EVs. A) Cellular component of overlapped proteins between DR urine EVs
and DR retina EVs. Components are enriched for organelles and structures involved in DR. B)
Biological pathways of overlapped proteins reveal that pathways are enriched for mechanisms
involved in DR.

To further analyze the pathways associated with this population of proteins we used
Figure 33. 43 Proteins
are upregulated 4-fold
and shared between urine
DR EVs and retina DR
EVs.

Panther Gene ontology database and
identified 38 genes from our EVs that
mapped to 19 biologic pathways.

(Figure 34). The top percentiles pathways were angiogenesis, CCKR signaling, dopamine
receptor signaling, integrin signaling and VEGF signaling, each correlated to DR

Figure 34. Biologic pathways of
upregulated proteins shared
between urine DR EVs and
retina DR EVs correlate to DR
pathogenesis.
Upregulated
proteins present in both urine and
retina EVs entered into Panther
gene ontology database shows
38 identified protein genes and 19
biologic pathways.
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pathogenesis. We then organized these proteins by class to analyze functional links to
DR and obtained 21 protein classes (Figure 35). The top percentile protein classes were
oxireductase, hydrolase, transferase and cytoskeletal protein.

The urine receives metabolites and molecular EV cargo from virtually every section of the
body. To further define a DR prognostic marker, EV protein signature should contain
markers for origination in ocular or retinal tissue. To narrow down our EV cargo source,
we analyzed the site of expression of the 96 proteins shared between urine DR EVs and
retina DR EVs (Figure 36). Using FunRich analysis, 41 of the 96 proteins shared between
urine DR EVs and retina DR EVs originated in retina, tears, lens and nervous
system (Figure 36). These tissue and cell
sources were then analyzed for protein
classes and 40 of the shared EV proteins
mapped to 29 protein classes including
transferase, hydrolase, oxireductase and
nucleic acid binding (Figure 37).

Figure 35. Upregulated proteins present in
both urine and retina show protein class
associations with DR pathogenesis. The input
analysis was 38 identified genes and resulted in
21 protein classes.

Similarly, the 4-fold or greater upregulated
proteins shared between urine DR EVs and

Figure 36. FunRich analysis showing site of tissue
and cell expression for proteins shared between
urine DR EVs and DR retina EVs. Expression sites
were highly associated with ocular tissue, retina and
nervous system. FunRich was used to perform
hypergeometric test with Benjamini-Hochberg method
correction.
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retinal DR EVs were analyzed for site of expression and 43 mapped to retina, tears, lens,
nervous system and ARPE-19 cell lines. (Figure 38A). From our analysis 31 were
identified in the nervous or visual system. Genes found within the retina included ITGAV
and Ceruloplasmin313-315 We then used STRING analysis to map interactions between
the 31 proteins (Figure 38B).

Figure 37. Analysis showing protein class for
overlapped protein signatures from urine and retina
EVs. Our input of 40 mapped genes yielded 29
protein class hits.

A

B

Figure 38. 4-fold or greater upregulated proteins shared between urine DR EVs and retinal DR
EVs map to sites of ocular expression including retina, tears and lens.
A) FunRich analysis showing site of expression for overlapped upregulated protein signatures.
Expression sites were limited to nervous system or visual components. B) STRING pathway analysis
of 31 protein identified from nervous or visual system in severe DR urine and DR retina EV. FunRich
was used to perform hypergeometric test with Benjamini-Hochberg method correction.
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Figure 39. Urine and Retina EV
proteins show predicted association
with
retinal
degeneration.
Upregulated proteins shared between
urine DR EVs and retina DR EVs
associate with clinical phenotypes in
the visual system to eyes (27.3%) and
retinal degeneration (9.1%).

Lastly, the 31 identified 4-fold or greater upregulated proteins belonging to the nervous
or visual system were analyzed for associated clinical phenotypes using FunRich
enrichment. The highest percentile phenotypes included miscellaneous (72.7%), central
nervous system (54.5%) and neurologic (63.6%) (data not shown). When refining the
FunRich association to visual system categories including eyes (27.3%) and retinal
degeneration (9.1%) are present. Figure 39. These results suggest that urine DR EV and
retina DR EV proteins originate from ocular tissue be useful a prognostic DR markers.

5.4. Next Generation Sequencing from diabetic and non-diabetic human urine EVs
Figure 40. Urine EVs contain miRNA
signatures that play a role in DR. A) Venn
diagram showing miRNAs present in non-diabetic
(262), no DR (269), mild NPDR (199) and severe
NPDR (279) urine. B) Venn diagram normalized
against non-diabetic species showing miRNAs
present in no DR (30), mild NPDR (8) and severe
NPDR (37) urine. C) Functional enrichment
analysis of no DR species against NPDR species
showing enrichment for processes including
wound healing, anti apoptosis, cytoskeletal
organization and depletion in processes like cell
adhesion, inflammatory response and cell death.
D) Functional enrichment analysis for miRNA
species found in NPDR samples showing
pathways associated with DR including VEGF
signaling, mTOR signaling, Arf6 downstream
pathway, beta integrin cell surface interactions
and endothelins. FunRich was used to perform
hypergeometric test with Benjamini-Hochberg
method correction
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Small RNA NGS was performed on EVs isolated from patient urine of non-diabetic,
diabetic without DR, and diabetic with mild, moderate or severe DR. The numbers of
samples per group included non-diabetic (ND) (n=3), diabetic with no DR (n=3), diabetic
with mild NPDR (mild) (n=3) and diabetic with severe NPDR (severe) (n=3). Fundus
images of each diabetic patient are available in supplemental data (Figure S3). NGS
analysis identified several miRNA species within EVs isolated from patient urine. The
following numbers of miRNA species were identified: control non-diabetic = 262 species,
diabetic no DR = 269 species, mild DR - 199 species and severe DR = 279 species
(Figure 40A). Next, control miRNAs, present in non-diabetic urine EVs, were removed
and a Venn diagram generated specific for miRNAs present in diabetic urine EVs (Figure
40B). The data show that six miRNA species are present in urine from diabetic without
DR EVs (hsa-miR-182-3p, hsa-miR-1261, hsa-miR-3127-5p, hsa-miR-338-5p, hsa-let-7f2-3p and hsa-miR-424-5p). In mild DR urine EVs, a single species was exclusively
detected (hsa-miR-509-3-5p). In severe DR EVs twelve exclusive miRNAs were detected
(hsa-miR-485-5p, hsa-miR-323a-3p, hsa-miR-145-3p, hsa-miR-493-5p, hsa-miR-708-3p,
hsa-miR-199a-3p, hsa-miR-485-3p, hsa-miR-130a-3p, hsa-miR-129-1-3p, hsa-miR-5763p, hsa-miR-548ba and hsa-miR-5187-5p). Two species (hsa-miR-128-1-5p, hsa-miR22-5p) overlapped between mild and severe DR EVs for a total of 15 within the NPDR
group. To study enrichment within NPDR miRNA populations, FunRich software was
utilized to revealed fold change differences in biological processes between diabetic no
DR EV miRNA species (n=6) and the NPDR exclusive species (n=15) (Figure 40C). Both
highly enriched and depleted biologic processes were identified and correlated to DR
pathogenesis.
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Figure 41. NPDR patient urine EV miRNAs
have strong interactions with genes
associated with DR. A) Diagram showing
network map of miRNA species found within
NPDR urine EV samples and their target
genes. Enlarged diagram shows target genes
with strong interactions. Strong interactions
are indicated by green lines, more than 2
interactions are orange while 2 interactions
are colored blue. miRNAs are shown in brown.

Enriched

processes

included

anti-

apoptosis, wound healing, cytoskeleton organization, fatty acid metabolism and
chromosome segregation. Depleted processes included cell adhesion, inflammatory
response, cell death, vesicle mediated transport and microtubule based processes.

To predict gene targets of identified NPDR urine EV miRNA species miRTarget Link
Human
was

database
used

and

network maps from
NPDR

Figure 42. Urine EV miRNAs from NPDR and diabetic retina EVs
regulate processes involved in DR. A) Venn Diagram showing overlap of
miRNAs present in diabetic retina EVs and miRNAs present in NPDR urine
EVs exclusively. B) Functional enrichment analysis of 13 miRNA species
identified in overlap between diabetic retina EVs and miRNAs present in
NPDR urine EVs exclusively show significant enrichment in pathways
related to DR pathogenesis. FunRich was used to perform hypergeometric
test with Benjamini-Hochberg method correction.

exclusive

miRNA

species

created.

Network

analysis

identified

147 genes that were
targeted by 2 or

more NPDR urine EV miRNAs. Four genes associated with DR (MET, MAPK1, IGF1 and
ATXN1) were identified with strong interactions from 2 NPDR EV miRNA species hsamiR-199-3a and hsa-miR-130a-3p. (Figure 41).
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Figure 43. Urine EV miRNAs
from NPDR and diabetic retina
EVs show strong interaction to
target gene ATXN1. A) Diagram
showing networking map of
miRNA species found within
NPDR urine EV samples and
diabetic retina EVs and their
target genes. Enlarged diagram
shows target genes with strong
interactions. Strong interactions
are indicated by green lines and
more than 2 interactions are
colored
orange
while
2
interactions are colored blue.
miRNAs are shown in brown.

To determine if miRNA species were shared between patient urine EVs and retina EVs
we compared NPDR urine EV miRNA only species (n=15) and DR retina (tissue) EV
miRNA only species (n=21) and found no overlap. Next, we expanded the starting number
of miRNAs and compared the total DR retina (tissue) EV miRNAs (321) and total miRNAs
present in NPDR urine EVs (Figure 42A). With this analysis, 13 shared miRNA species
were identified (hsa-miR-485-5p, hsa-miR-323a-3p, has miR-145-3p, hsa-miR-493-5p,
hsa-miR-128-1-5p, hsa-miR-708-3p, hsa-miR-485-3p, hsa-miR-130a-3p, hsa-miR-1291-3p, hsa-miR-22-5p, hsa-miR-576-3p, hsa-miR-548ba, hsa-miR-5187-5p). Next to
identify gene targets of the 13 overlapping miRNA species, miRTarget Link Human
database was used. miRTarget analysis revealed that 109 genes were targeted by 2 or
more of the (13) miRNAs, including (ATXN1) with strong predicted

interactions

with one of the overlapping miRNA hsa-miR-130a-3p (Figure 43).

5.5. Discussion

Analysis of urine DR EVs showed that there are distinct differences in DR patient urine
vs non-diabetic urine relative to EV size, concentration and release or absorption rate. No
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previously published studies been shown a relationship between DR and EVs in urine.
There are a number of studies that have analyzed the relationship between diabetic
nephropathy (DN) and its effect on glomerulus and urine production. There is a direct
connection between DR and DN as they are both microvascular pathologies created by
uncontrolled diabetes.316,317 In both of these conditions pathogenesis induced by
hyperglycemia includes NOS production, increased permeability, endothelial dysfunction,
activation of PKC and AGEs productions.318-323 George et al. demonstrated that in
diabetic conditions the concentration of EVs in urine is significantly increased when
compared to non-diabetic control. 307

In this work, the proteomic signature analyzed in severe DR urine contains more diverse
species compared to non-diabetic control, which may be attributable to the increased
metabolic stress in diabetic conditions. Our analysis identified novel EV proteins, not
found within the Vesiclepedia database, that associate with DR pathways. Protein
analysis showed gene networks associated with DR including VEGF, TRAIL, EGFR and
PAR-1 mediated thrombin signaling. TNF related apoptosis inducing ligand (TRAIL) is a
membrane protein belonging to the tumor necrosis family (TNF), involved in inducing
apoptotic mechanisms and associated with the pathogenesis of diabetes through cytokine
production and pancreatic dysfunction.324-326 TRAIL has been shown to increase the
production of nitric oxide which is a precursor for NOS and is an early mediator of DR
onset.

327

These studies also show TRAIL increases the production of prostanoid which

has been shown to be involved in angiogenesis and vascular dysfunction.324,328,329 330,331
Epidermal growth factor receptors (EGFR) are tyrosine kinases that contain 4 members
that include EGFR (erbB1), EGFR2 (erbB2, Neu, HER2), EGFR3 (erbB3) and EGFR4
(erbB4).332

This receptor family regulates essential cellular functions including cell
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growth, apoptosis, differentiation and survival.333 EGFR has been implicated in diabetesrelated ER stress and is a target for therapeutic intervention. 334 In diabetic conditions
hyperglycemia has been shown to affect the EGFR-PI3K-AKT signaling pathway by
increasing cellular apoptosis335. EGF signaling has also been implicated in retinal
vasculature damage. Sugimoto et al. published a study using diabetic mice treated with
EGFR inhibitors in the presence of insulin and showed reduced retinal vascular
damage.336,337 Protease-activated receptor-1 (PAR-1) is a G-protein coupled receptor
(GPCR) that has been shown to be involved in proliferation, differentiation and
angiogenesis.338-340 PAR-1 levels have been shown to be increased in the vitreous of
patients with proliferative DR and is hypothesized to be involved in angiogenesis.341 The
angiogenic characteristic of PAR-1 is predicted to be functional through the VEGF
signaling pathway.342-344 From these observations we can see that novel protein EV
signatures from DR urine contain pathways that are enriched for the pathogenesis of DR.

Analysis of the total population of proteins found within DR urine EVs also shows
enrichment for molecular functions including hydrolase, oxireductase, cellular adhesion
and transporter activity, which are predicted to be related to the increased metabolic
activities in DR. The total urine DR EV proteins signaling pathways also align with DR
pathogenesis and include insulin synthesis and processing, diabetes pathway and
eukaryotic translational mechanisms. These pathways all signify an enrichment for DRrelated processes and indicate that urine DR EV cargo possesses traits similar to DRdiseased origin tissue.

The utilization of urine EVs as a prognostic for DR is reliant on the molecular signatures
that are secreted from both urine DR EVs and retinal EVs. Our analysis has reported EV
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protein signatures that appear unique to urine DR EVs and retina DR EVs. The data
revealed shared protein signatures between urine DR EVs and retina DR EV that may
allow for diabetic urine EVs protein signatures to be used as prognostics of DR onset and
progression. The cellular component location of these identified overlapped proteins is
concentrated in organelles such as the mitochondria, lysosomes and endoplasmic
reticulum, which suggest their roles in DR may be related to mitochondrial dysfunction,
peroxidase activity, production of ROS and ER stress proteins. These cellular
dysfunctions are central to the development and progression of DR. The pathways these
molecular signatures are implicated in were also found in the top percentiles, including
VEGF signaling, mTOR signaling, EGF receptors, integrin interactions and Arf6 signaling
interactions (Figure 28). These pathways facilitate DR conditions, including growth of new
blood vessels, mitochondrial dysfunction, production of reactive species, endothelial
dysfunction, inflammatory response and production of AGEs. The enrichment of these
categories from both diabetic retina and diabetic urine EVs demonstrate that EV
signatures may be used as a positive indicator of disease progression.

Our analysis also examined upregulated protein signatures that overlapped between
severe DR urine EVs and DR retina EVs. The results found 43 proteins that overlapped
between severe urine DR EVs and retina DR EVs (Figure 33). These upregulated proteins
associated with pathways related to DR pathogenesis include angiogenesis, VEGF
signaling, Integrin family signaling and metabolism. Analyses of the molecular function
associated with the 43 upregulated species also showed categories aligned with DR
including oxireductases, cell adhesion, hydrolases, transferases and transporters.
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The urine is comprised of metabolites and molecules from an assortment of bodily
tissues. To determine the source of EVs isolated from DR urine, we analyzed for markers
of ocular and retinal tissue. In Figures 44 and 46, the sites of origin include eyes and
retina, among others.

The data show that a percentage of upregulated proteins shared between urine DR EVs
and retina DR EVs show sites of origin in the eye. From both populations, the specific
proteins shown to be found in the retina included integrin alpha 5 (ITGAV), ceruloplasmin
(CP), retinol dehydrogenase 10 (RDH10), cytochrome B-245 Beta Chain (CYBB),
coenzyme A synthase (COASY) and heat shock protein family D (Hsp60) member 1
(HSPD1). The relationship of these proteins to DR include that CP serum expression is
increased; CP has been shown to be a predictor of DR progression and is responsible for
oxidative stress responses.

273,345,346

ITGAVs role in DR is predicted to be related to

angiogenesis, cell adhesion and leukocyte migration and AGE related endothelial
dysfunction.347

348,349

RDH10 has been shown to be increased in impaired insulin

secretion and insulin resistant patients.350,351 The CYBB gene also known as NOX2 has
been shown to upregulate in DR and is responsible for ROS and inflammatory
responses.352-354 COASY is a molecule that is used primarily in energy metabolism and
is important for glycemic control.355 HSPD1

has been shown to be involved in

mitochondrial activity and is related to DR through its role in mitochondrial dysfunction
and stress response.356 HSPD1 levels have been shown to be upregulated in diabetic
retinopathy compared to control.

357

In summary, the data suggest that urine EV

proteomic cargo signatures can be associated with ocular and retinal tissue and may be
used as a DR prognostic.

88

To our knowledge this is the first study to use NGS to analyze diabetic retina and DR
urine EVs to identify miRNA cargo with potential function in DR pathogenesis. For urine
EV analysis miRNA normalization was performed to remove non-diabetic and diabetic
with no DR EV miRNA, and 15 miRNA species were identified unique to NPDR mild and
NPDR severe. Functional enrichment identified pathways associated with these (15)
miRNAs and correlation to DR pathways was revealed, including VEGF, PAR1, mTOR
and endothelins. Each of these pathways have been shown to be involved in the
pathogenesis of DR and include target genes of the above 15 miRNA species.
Overexpression analysis of the 15 miRNAs showed weak interactions with 147 genes
and strong interactions with 4 genes, 3 of which have established association with DR
pathogenesis including MET, MAPK1, IGF1. MET also known as Hepatocyte Growth
Factor Receptor is specific to the endothelium and has been shown to be involved in DR
by increasing retinal vascular permeability with elevated levels in DR individuals.358-361
Similarly, IGF1 has been shown to be involved in the pathogenesis of DR by stimulating
pathways including VEGF, HIF-1, intracellular adhesion molecule and NF-kappa B.362-364
ATXN1 is the fourth gene strongly interacting with the above 15 miRNAs and at this point
has not been shown to be involved DR. Its mutant form has been shown to cause
spinocerebellar ataxia-1 (SCA1) and neurodegeneration. Mutations in the ataxin 7 protein
have also been shown to cause retinal degeneration in the SCA7 condition.365-368

In the later stage of analysis retina (tissue) EV miRNA was compared to urine EV miRNA
species to search for overlapping species. Comparison of DR retina (tissue) EV miRNA
only species (n=21) to NPDR urine EV miRNA only species (n=15) showed no overlap.
Next, expanded starting numbers of miRNAs compared total DR retina (tissue) EV
miRNAs (321) and total miRNAs present in NPDR urine EVs. With this analysis, 13
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shared miRNA species were identified (hsa-miR-485-5p, hsa-miR-323a-3p, has miR-1453p, hsa-miR-493-5p, hsa-miR-128-1-5p, hsa-miR-708-3p, hsa-miR-485-3p, hsa-miR130a-3p, hsa-miR-129-1-3p, hsa-miR-22-5p, hsa-miR-576-3p, hsa-miR-548ba, hsa-miR5187-5p). Using miRTarget link human database, theses overlapping urine EV miRNAs
from NPDR and diabetic retina EVs are predicted to regulate pathways involved in DR.
Further studies will be helpful in defining functional significance of these overlapping
miRNA in DR pathogenesis.

5.6. Materials and Methods

5.6.1. Urine collection
Patients who fit the criteria as designated by our IRB document were asked to urinate in
a urine cup during their routine examinations. Patients were informed about the study and
signed a waiver for use of their samples in our experimental design.

5.6.2. EV isolation from urine
Removed urine from freezer and allow to thaw completely. Add 1 tablet of Roche Protease
inhibitor per 50mL of sample and vortex. Centrifuged urine sample at 1500RPM for 10
min to remove dead cell and cell debris. Spun urine for 10 mins at 13000RPM. Collected
the supernatant and save for later use. Dissolved 100mg of DTT in 500uL of isolation
buffer and dissolve pellet from centrifuge tube into solution. After dissolving incubated at
37C for 10 min. After incubation filled tube with isolation solution and spin at 13000RPM
for 10 min at 4C. After centrifugation collect supernatant and combine with supernatant
from previous spin. Spun supernatant samples for 70 mins at 33000RPM at 4C. After
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centrifugation discarded supernatant and resuspend pellet in 100mg of DTT dissolved in
500uL of isolation solution and incubated at 37C for 10min. After incubation add 25mL of
isolation buffer to dissolved pellet and spin at 49000RPM for 70mins at 4C. After
centrifugation removed supernatant and dissolve pellet in 400uL of Trizol and continued
with RNA isolation protocol.

5.6.3. Nanosight analysis
EV diameter and concentration were assessed using the NanoSight NS500 system.
Retina conditioned media was collected at 5 days of culture and transferred to centrifuge
tubes. Media was centrifuged at 300g × g for 5 minutes supernatant was transferred to a
centrifuge tube then spun at 500g for 10 minutes then repeated the process again at
3000g for 20 minutes. Control non-conditioned media was processed using identical
steps. Supernatant was diluted at 1:20 in PBS and 1ml was used for NanoSight analysis.
Nanoparticle Tracking Analysis (NTA) software 2.3 was used to track trajectories and
diameters of nanoparticles. Results are displayed as frequency sized distribution graphs
describing the number of particles per milliliter. The concentration of released EVs was
calculated to determine the average number of EVs with standard deviation in conditioned
media compared to control and analyzed using a Student’s t-test.

5.6.4. Transmission Electron Microscopy (TEM)
EVs isolated from urine were fixed in 2.5% glutaraldehyde with 4% paraformaldehyde
(EM grade) for 2.5 hours and washed in PBS for 24 hours. EVs were post-fixed in osmium
tetraoxide for 30min, washed with distilled water and subsequently dehydrated using
increasing ethanol concentrations (70%, 85%, 95% and 100%), each for 10 minutes.
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Sample dehydration was followed by immersion in propylene for 20 minutes twice.
Samples were infiltrated with a 1:1 mixture of propylene oxide and Spurr’s Resin for 1
hour, left in 100% Spurr’s Resin overnight. Samples were then embedded in beem
capsules using fresh Spurr’s Resin at 70°C for polymerization. Excess resin was trimmed
and 90 nm sections of samples were made using a Leica Ultramicrotome. Sections were
placed on 200 mesh copper grids, stained with saturated uranyl acetate in 50% ethanol
for 6 minutes, rinsed in water and stained for 90 seconds in lead citrate. Grids were then
rinsed in water, dried on filter paper and viewed under a Fei Tecnai transmission electron
microscope operated at 80 kV. Images were obtained using an AMT camera with AMT
digital software.

5.6.5. RNA Isolation
Total RNA was extracted and purified from urine EV pellets using the Trizol Reagent
according to the manufacturer's protocol. Added .04 ml of Trizol to the tissue/ EV sample.
Incubated for 5 minutes to permit complete dissociation of the nucleoproteins complex.
Added.08ml of chloroform and incubated for 2–3 minutes and centrifuged the sample for
15 minutes at 12,000 × g at 4°C. Transferred the aqueous phase containing the RNA to
a new tube. Added 0.2ml of isopropanol to the aqueous phase, per 1 mL and incubated
for 10 minutes. Centrifuged for 10 minutes at 12,000 × g at 4°C. Discarded the
supernatant with a micropipettor and resuspended the pellet in .04ml of 75% ethanol per
1 mL of TRIzol Reagent used. Vortexed the sample briefly, then centrifuged for 5 minutes
at 7500 × g at 4°C. Discarded the supernatant with a micropipettor and air dried the RNA
pellet for 5–10 minutes. RNA was diluted in 50ul of Nuclease free water and stored at 80°C.
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5.6.6. Protein Isolation
For EV protein isolation centrifuged pellet was dissolved in 200ul PBS and used for
downstream applications. Protein concentrations were obtained through BCA assay.

5.6.7. NGS analysis
For NGS of retinal EVs, small RNA Libraries were generated using a NEBNext® Multiplex
Small RNA Library Prep Set for Illumina (NEB, Ipswich, MA) (PMC5975555). For
exosomal RNA isolated from cell culture media, approximately 1 ng was used as input for
library generation. Three biological replicates were used for each of the experimental EV
media. The Multiplex Small RNA Library prep set has an input concentration range and
does not rely on starting the library using an equal RNA amount. The libraries were
prepared according to the manufacturer’s instructions. The amplified libraries were
resolved on Novex® 6% TBE Gels (Thermo Fisher, Waltham, MA). Library fragments
were excised and further purified using a RNA Clean-up and Concentration Micro-Elute
Kit (Norgen Biotek, Thorold, Ontario). The indexed libraries were quantified using the High
Sensitivity DNA Kit (Agilent, Santa Clara, CA). All libraries derived from EVs were pooled
together for a final pooled library at a final concentration of 4nM. Normalization of libraries
after size selection is the used method for small RNA Sequencing. The libraries were
pooled using equal molarities from the NGS library of each sample. The pooled library
was then sequenced on an Illumina MiSeq using version 3 reagents by Norgen Biotek
Corp. A small RNA expression profile was generated from the resulting FASTQ files using
the exceRpt small RNA-seq pipeline [56]. Sequencing was quality controlled using a
Nanodrop ND/1000 spectrophotometer.
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Read mapping and small RNA annotation
The sequence raw data from the Illumina HiSeq 4000were converted to fastq format. Files
were then used in the Genboree Workbench’s exceRpt small RNA-seq pipeline
(version 4.6.2) for read mapping to the hg38 human genome version [66]. This allowed
for a single mismatched base down to 18 nucleotides. After adapter trimming, read quality
was assessed by FASTQC to filter out reads with a quality score lower than 30 on the
PHRED

scale.

Reads

were

first

mapped

to

the

UniVec

and human ribosomal RNA (rRNA) sequences to exclude them before mapping to
databases of miRBaseversion 21, gtRNAdb and piRNABank to assign reads to miRNAs,
tRNAs and piRNAs, respectively. Identified t RNAs are tRNA-derived RNA fragments due
to the fact that the library insert size is below 50nt. Remaining sequences were then
annotated to gencode version 24(hg38) which includes protein coding transcripts (protein
coding),

mitochondrial

mitochondrial tRNA (Mt_tRNA),

rRNA

(Mt_rRNA),

small nuclear RNA(snRNA), small nucleolar RNA

(snoRNA), long inter-genic noncoding RNA (lincRNA) and miscellaneous RNA
(misc_RNA).

Data analysis
Raw read counts obtained from the Genboree Work-bench’s exceRpt small RNA-seq
pipeline were further analyzed using R (version 3.5.2). The following R packages were
used in the analysis: RnaSeqGeneEdgeRQL (version 1.4.1) for counts per million (CPM)
filtration and normalization by using trimmed mean of M-values (TMM) [67], ggfortify
(version 0.4.5) and Complex Heatmap (version 1.20.0) for principal component analysis
(PCA) plot and heatmaps based on the filtered and normalized data, respectively. Venn
Diagram (version 1.6.20) was used to illustrate Venn diagrams.
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5.6.8. qPCR analysis
Total RNA (1 µg) was reverse-transcribed to produce complementary DNA (cDNA) using
the New England Biolabs Protoscript AMV First Strand cDNA Synthesis Kit according to
the manufacturer’s protocol. Briefly, isolated RNA was mixed with d (T) 23 primer and
denatured for 5 min at 70°C.

AMV reaction mix buffer, enzyme mix of reverse

transcriptase and murine RNase inhibitor was added to the sample and incubated at 42°C
for 1 hour. The AMV enzyme was inactivated via incubation at 80°C for 5 min. The cDNA
product was diluted with 30μl nuclease-free water and analyzed using SYBR Green ER
qPCR Supermix. According to the iCycler protocol 12.5µL of SYBR GreenER qPCR
Supermix, 0.5µL of forward and reverse primers and 1µL of cDNA template were
combined and DEPC water added to bring the volume to 25µL. Samples were prepared
in triplicates and mixed in a PCR plate followed by amplification and melting curve
analysis using a Bio-Rad iCycler.

5.6.9. Mass spectrometry
EV-enriched samples from human urine were denatured in 8M urea, reduced with 10mM
DTT, and alkylated with 50mM iodoacetamide. This was followed by proteolytic digestion
with endoproteinase LysC (Wako Chemicals) overnight, and with trypsin (Promega) for
6h at room temperature. The digestion was quenched with 2% formicacid and resulting
peptide mixtures were 44. Samples were dried and resolubilized in 2% acetonitrile and
2%formic acid. Approximately 1μg of each sample was injected for analysis by reversed
phasenano-LC-MS/MS (Ultimate 3000 coupled to a QExactive Plus, Thermo Scientific).
After loading on a C18 trap column (PepMap, 5μm particles, 100μm x 2cm, Thermo
Scientific) peptides were separated using a 12cm x 75μm C18 column (3μm particles,
Nikkyo Technos Co., Ltd. Japan) at a flow rate of 200 nL/min, with a gradient increasing
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from 5% BufferB (0.1% formic acid in acetonitrile) / 95% Buffer A (0.1% formic acid) to
40% Buffer B / 60%Buffer A, over 140 minutes. All LC-MS/MS experiments were
performed in data dependent mode with lock mass of m/z 445.1200345. Precursor mass
spectra were recorded in a 300-1400m/z range at 70,000 resolution, and fragment ions
at 17,500 resolution (lowest mass: m/z 100). Up to twenty precursors per cycle were
selected for fragmentation and dynamic exclusion was set to 60 s. Normalized collision
energy was set to 27.

5.6.10. Protein profiling analysis
Mass spectrometry data were searched against a human database using MaxQuant
(version 1.5.0.30 45). Oxidation of methionine and N-terminal protein acetylation were
allowed as variable modifications, while all cysteines were treated as being
carbamidomethylated. Precursor mass tolerance was set at 4.5 ppm while a 20 ppm
tolerance was allowed for fragment ions. Two missed cleavages were allowed for specific
tryptic search. The “match between runs” option was enabled. False discovery rates at
the protein and peptide level were set to 1%.

5.6.11. Proteome Discoverer Analysis
Identified peptides were filtered using 1% False Discovery Rate (FDR) and Percolator.
Proteins were sorted out according to highest area. The area is calculated based on the
3 most abundant peptides for the respective protein. Proteins not detected or present in
low amounts are assigned an area zero. Data were extracted and queried against the
human database using Proteome Discoverer and Mascot..300,301
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5.6.12. Bioinformatics analysis
Functional enrichment analysis was done using the FunRich software for both protein and
miRNA enrichment analysis. Protein classifications were analyzed using the Panther
Gene Ontology classification system. miRNA targeting networks were analyzed using
miRTargetLink Human database.

6. Conclusion
Our study has been one of the first to try and understand the proteomic and miRNA cargo
of EVs in human retina with DR and patient urine with DR. We have successfully
demonstrated that retinal tissue releases EVs and our analysis sought to quantify and
characterize the cargo. The data show that the molecular cargo present in EVs from both
tissue and urine samples have a range of disease associated proteomic and miRNA
cargo. The data reveal that detected retina EV protein and miRNA species are also
detected in urine EV protein and miRNA signatures. Further analysis of DR EV differential
expression may identify targets for DR treatment and further refine EV as biomarkers for
DR development, progression and response to treatment.
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